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ABSTRACT OF DISSERTATION

CHARACTERIZATION AND ENGINEERING OF HUMAN PROTEINS AS
THERAPEUTIC CANDIDATES

Protein engineering has been a useful tool in the fight against human diseases.
Human insulin was the first recombinant DNA-derived therapeutic protein (Humulin®)
approved by the US FDA in 1982. However, many of the early protein drugs were only
recombinant versions of natural proteins with no modification of their primary amino
acid sequence and most of them did not make optimal drug products mainly due to their
short half-life or suboptimal affinity, leading to poor therapeutic efficacy. The difficulty
in the large-scale production of some therapeutic proteins was another important issue.
In the past three decades, different protein engineering platforms have been developed to
overcome the obstacles seen in the first generations of these treatments. With the help of
these new techniques, proteins have been purposefully modified to improve their clinical
potential. The focus of my dissertation is the engineering of potential protein drugs to
make them therapeutically useful and more valuable. Previously, our research group has
developed cocaine hydrolases (CocHs) from human butyrylcholinesterase (BChE) for
treatment of cocaine addiction and prevention of acute cocaine intoxication. In the first
project, CocHs were further engineered to improve their performance, e.g., Fc-fused
CocHs with an extended serum half-life. Then, I investigated the potential application of
a long-lasting CocH for protection against the acute toxic and stimulant effects of cocaine.
In the second project, I investigated the potential inhibition of CocH-mediated cocaine
hydrolysis by heroin (3,6-diacetylmorphine) or its initial host metabolite, 6monoacetylmorphine (6-MAM). The investigation of this possible inhibition was
important to determine the in vivo efficacy of CocHs, as heroin is one of the most
commonly co-abused drugs by cocaine-dependent individuals, as well as a possible
metabolite of CocHs. In the third project, I expressed and characterized the recombinant
human UDP-glucuronosyltransferase 1A10 (UGT1A10) enzyme, which can inactivate
many therapeutically valuable substances. In the fourth and final project, prostate
apoptosis response-4 (Par-4), a tumor suppressor protein, was engineered to have a
prolonged duration of action so that it may be more therapeutically valuable for cancer
treatment.
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Chapter Ⅰ. Introduction
1.1 Protein therapeutics
Multiple human proteins have been developed as therapeutic protein drugs since
the introduction of recombinant human insulin in 1982.1 Therapeutic protein drugs have a
critical advantage over small-molecule drugs that are currently more dominant in the
pharmaceutical market.2-4 They perform highly specific and complex functions that are not
easily mimicked by small molecules.5-6 For example, some human diseases that were
previously not treatable or are characterized by congenital deficiency or acquired loss of a
functional endogenous protein (e.g. diabetes,7 dwarfism,8-9 infertility,10 chronic renal
failure,11 Gaucher disease,12-13 and certain cancer types14-17) can now be successfully
managed by using protein therapeutics.18 Indeed, protein replacement therapy has been
considered a suitable alternative to gene (replacement) therapy for the disease conditions
where gene therapy is currently inapplicable to treatment.19-20 The development of new
protein drugs has accelerated the changes in the treatment paradigm of many different
diseases.
Natural human proteins were not originally evolved for therapeutic purposes.
Therefore, most of them do not have the intrinsic activity, affinity, and/or stability sufficient
to treat diseases within patients.5, 21-23 They usually have a short circulating half-life, low
thermal stability at physiological temperature, or suboptimal affinity, which in turn results
in limited therapeutic efficacy and frequent dosage.24 In addition to this, many of them are
difficult to produce in large-scale,25-27 which usually leads to a greatly increased cost of
pharmaceutical commercialization.27 In general, the use of these drugs is limited in routine

1

clinical practice due to the high cost.26 Because of these reasons, substantial improvements
have been made in the stability, pharmacokinetics, pharmacodynamics, and production
yield of multiple human proteins to make them become therapeutically and commercially
viable.14, 28

1.2 Improvement of activity
Improved versions of human protein therapies can be developed by improving both
functionality and efficiency.34-39 Our increasing understanding of the structural and
functional relationship of multiple human proteins to their mechanisms of action enables
us to more rationally re-design and engineer them to induce an improved activity or even
novel functionality.29-30 A number of protein engineering strategies are currently in use for
not only the optimization of existing therapeutic proteins, but for the introduction of novel
protein drugs for specific clinical applications as well.29-32 Here, I will describe an example
of rational modifications to a current protein drug, accomplished by protein engineering,
that has resulted in both the development of the next generation of therapeutic proteins and
the approval of novel therapeutic proteins for the treatment of other diseases. Human
Interleukin 2 (IL-2) is an example of a protein has been genetically modified for clinical
use. Proleukin® (Chiron Corporation) was the first recombinant human IL-2 variant
produced in E. coli.33-35 This aglycosylated therapeutic protein differs from natural human
IL-2 by a substitution of cysteine for serine at position 125 for increased stability and the
removal of an N-terminal alanine residue for increased production yield in E. coli. The
biological activity of Proleukin® was proven similar to that of the wild-type human IL-2,36
and the drug has been approved by the FDA for treatment of metastatic melanoma and
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metastatic renal cell carcinoma.33, 37 However, it has been reported that high doses of IL-2
utilized for treatment of these types of cancer causes significant toxicity to humans due to
its capability to activate natural killer (NK) cells.38-39 Therefore, in order to reduce toxicity
and improve tumor suppressor activity, IL-2 has been further engineered to have an
increased binding affinity for its receptor (known as CD25 ) observed on the cell surface
of human T cells, but with no increased interaction with IL-2 receptors on NK cells. The
discovered high-affinity IL-2 variant has proven considerably more potent in activating
human T cells compared to that of the native human IL2.40-41 This may imply that enhanced
T cell activation by the IL-2 analog would permit lower dosage in the clinic and therefore
a reduced chance for adverse effects. In addition, fusion of IL-2 to a toxin (e.g. Aerolysin,42
diphtheria toxin,43-44 Denileukin diftitox (Ontak®)45-46) has been developed for other
clinical applications such as the treatment of cutaneous T-cell lymphoma expressing high
levels of the CD25 component of the IL-2 receptor.47-48 In this case, IL-2 is used as a
homing molecule to deliver a conjugated toxin to the target lymphoma.

1.3 Fusion proteins for half-life extension of protein therapeutics
The therapeutic efficacy of a therapeutic protein drug in the human body also can
be greatly increased by improving its pharmacokinetic profile.28, 49-54 Market pressures for
better patient compliance and treatment cost-effectiveness have created a great demand for
a therapeutic protein drug whose therapeutic efficacy can be sustained even at long dosing
intervals. Because of these reasons, multiple protein engineering platforms have been
developed to extend the circulating half-life of a therapeutic protein. Examples of such
platform technologies include protein PEGylation55 and protein fusion with the Fc region
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of human IgG1 (IgG Fc)56-57 or human serum albumin (HSA).58 These strategies have been
the most widely employed to prolong the duration of action of protein therapeutics.
The endothelial cellular neonatal Fc receptor (FcRn) has a critical role in
maintaining the high circulating levels of IgG and HSA.59-60 Indeed, immunoglobulin G
has a prolonged circulating half-life of 21 days mainly due to FcRn-mediated recycling
that protects against intracellular endocytic-lysosomal degradation.61-62 Intriguingly, this
property is also shared with HSA. IgG Fc or HSA strongly interacts with FcRn in the acidic
endosomal compartment (pH 6.0) after being internalized into endocytic vesicles.63 These
receptor-bound proteins are then returned to the cell membrane for extracellular release,
whereas other serum proteins in the vascular endothelium are eventually degraded by the
endocytic-lysosomal system.64-65 Fusion to IgG Fc or HSA prolongs the circulating halflife of a therapeutic protein by exploiting the FcRn-mediated recycling mechanism.66-68
Interestingly, genetic conjugation to IgG Fc or HSA also provides additional
benefits such as increasing both protein production and secretion,69-70 and enabling simple
purification by affinity chromatography.57, 71-72 A number of Fc- and albumin-fused biotherapeutics have been approved by the FDA or are currently under development.73 A
significant research effort on engineering the Fc region and HSA for improved
pharmacokinetics has demonstrated that enhanced binding affinity at pH 6 for FcRn further
extends the biological half-lives of the fusion proteins.74-77 For example, when a Fc variant
with improved FcRn binding affinity was constructed in the context of bevacizumab
(Avastin®, Genentech/Roche),78 a humanized anti-VEGF IgG1 antibody, the Fc
engineered antibody showed an approximately three and five-fold extension of the naïve
bevacizumab’s half-life in human FcRn transgenic mice and a non-primate model,
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respectively.76,

79-81

Inspired by these promising pharmacokinetic bioengineering

technologies, we have developed several novel therapeutic proteins with a prolonged
duration of action for treatment of cocaine addiction or cancer. These novel therapeutic
entities are expected to not only be more protective against elimination by cellular
endolysosomal degradation, but also eventually provide greater dosing convenience for
treatment.
This thesis research consists of four different projects. The first project is described
in Chapter ⅠⅠ. In the first project, cocaine hydrolases (CocHs) were engineered to have a
prolonged duration of action in vivo. Then, I investigated the potential application of a
long-lasting CocH for protection against the acute toxicity and stimulant effects of cocaine.
In the second project included in Chapter III, I investigated the potential inhibition
of CocH-catalyzed cocaine hydrolysis by heroin (3,6-diacetylmorphine) or its initial host
metabolite, 6-monoacetylmorphine (6-MAM). Because heroin is one of the most
commonly co-abused drugs by cocaine-dependent individuals, as well as a possible
metabolite of CocHs, the investigation of this possible inhibition was important to
determine the in vivo efficacy of CocHs.
In the third project described in Chapter IV, I expressed and characterized
extrahepatic human UDP-glucuronosyltransferase 1A10 (UGT1A10) enzyme, which can
inactivate many therapeutically valuable substances including morphine.
In the last project included in Chapter V of this dissertation, prostate apoptosis response-4
(Par-4), a tumor suppressor protein, was genetically engineered to have a prolonged
duration of action so that the protein may become more valuable for treatment of metastatic
tumor.
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Chapter Ⅱ. Development of a Long-acting Cocaine Hydrolase for Cocaine Abuse
Treatment

Cocaine, a highly pleasurable drug, is well-known for its high propensity to produce
dependent behavior as well as physical harm to the users.82-83 Cocaine use causes two
different, but closely related problems; addiction and overdose. Overall purpose of this
study is to develop a long-lasting enzyme therapy for treatment of cocaine addiction as
well as prevention of cocaine overdose. For this purpose, through a combination of
computational and experimental approaches, we have previously developed highly active
cocaine hydrolases (CocHs) by engineering butyrylcholinesterase (BChE). Especially,
CocH3 is proven to hydrolyze cocaine into biologically and physiologically inactive forms
with an approximately 2000-fold higher catalytic efficiency, compared to wild-type BChE.
However, according to our pharmacokinetic study of recombinant BChE and CocHs
prepared from mammalian expression systems, compared to natural BChE (11 days in
human), these recombinant enzymes are estimated to have limited in vivo half-lives (2-3
days in human),84 requiring twice weekly i.v. administration to retain its protective anticocaine activity in the circulatory system of human.85
To date, a number of commercially and clinically successful therapeutic proteins
have been generated as a fusion of both protein and the Fc region of immunoglobulin or
human serum albumin (HSA). Such fusions provide therapeutic proteins with the IgG or
HSA-like property of a long biological half-life as well as several other benefits such as
the increasing expression and secretion of the fusion protein and allowing simple
purification by affinity chromatography (protein A and ALBUPURE® chromatography). In
this study,86 we made the effort to improve the pharmacokinetic (PK) properties and
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potency of CocH3 by generating fusion proteins of CocH3 and the Fc region of human
IgG1 or HSA. It has been demonstrated that the fusion of CocH3 to our newly designed
human Fc variants (Fc(3m), Fc(4m), and Fc(6m)) have a substantially higher binding
affinity at pH 6 for human FcRn. These fusion CocHs had an increased half-life of more
than 28-fold in rats, compared to unfused CocH3. In addition, it was observed that FcRnmediated improvement of the enzyme further extended the duration of anti-cocaine activity
of CocH3 in the circulatory systems of rats and mice.87 These results might bridge the gap
for enhanced patient dosing convenience with the clinical need of maintaining therapeutic
efficacy of CocHs for cocaine addiction treatment. Moreover, the results of our protection
experiment demonstrated that pretreatment of rats with 3 mg/kg CocH3-Fc(3m) (i.v.)
before i.p. administration of a lethal dose (60 mg/kg) of cocaine completely blocked
physiological effects of cocaine on the brain. The pretreatment of CocH3-Fc(3m) not only
fully protected the animals from the hyperlocomotor activity induced by cocaine, but also
completely prevented changes in the subcellular localization of dopamine transporter (DAT)
from cytosol to the plasma membrane.
A manuscript for the results described in this chapter will be submitted for
consideration of publication. Both animal behavior and pharmacokinetic studies described
in this chapter were mainly performed by Ting Zhang and Xirong Zheng. Jing Deng
prepared the rat brain samples for the DAT distribution assay. The molecular modeling
study was performed by Drs. Yanyan Zhu and Yaxia Yuan. Dr. Zhenyu Jin helped me to
prepare cocaine hydrolases. Dr. Jinling Zhang contributed to FcRn binding assay. I
designed and performed all the rest experimental procedures described in this chapter.
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2.1 Treatment for cocaine abuse
2.1.1 Cocaine overdose and addiction
Cocaine is one of the most harmful drugs in the world.82 According to the 2007
National Survey on Drug Use and Health reports, about 36 million Americans aged above
12 years have abused cocaine at least once in their lifetime. At present, cocaine is the most
abused illicit drugs in America and was involved in 40.3% of illicit drug-related visits to
hospital emergency departments (EDs) in 2011 within the US.
Cocaine is well known for its euphoric high, physical harm, and high propensity to
produce dependence to the users.83 The physical harm caused by cocaine abuse is primarily
attributed to the strong cardiovascular effects of cocaine.88-93 Cocaine produces the feeling
of euphoria by majorly inhibiting the reuptake of dopamine, but it can also act as a
norepinephrine (noradrenaline) reuptake inhibitor (NRI).94-97 In the presence of cocaine,
more norepinephrine molecules remain active in the synaptic cleft for a longer than normal
duration. This leads to an exaggerated sympathetic nervous system response, imposing a
severe strain on the cardiovascular system. Indeed, when the activities of the heart are
intensified, a great cardiac need for oxygen and nutrients is created. However, the
constriction of capillaries induced by cocaine restricts the flow of blood to the heat muscle.
Consequently, the cardiovascular system becomes overburdened and, in the process,
cocaine users may encounter life-threatening heart issues such as myocardial infarction
(heart attack), and myocarditis (inflammatory cardiomyopathy). In fact, the continual use
of cocaine drastically increases the risk for these mentioned conditions as well as several
other cardiovascular issues within cocaine-addicted patients.98-99
Cocaine is often abused for recreational purposes and can cause serious substance
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addiction (AKA, substance use disorder).100-101 In general, substance addiction is defined
as a relapsing and chronic brain disorder that is characterized by uncontrollable and
compulsive seeking of a drug, despite the negative health and social consequences
associated with their use. Powerful psychoactive molecules such as cocaine and heroin
produce a two-part reaction in a user, the rush and high. The “rush” is an immensely intense
feeling resulting from the initial and acute psychological effects of a drug, and the euphoric
feeling following the rush is named as the “high” which often lasts over a period of several
hours after the drug intake.83 In fact, the psychostimulant effect of a drug is largely
dependent on not only its pharmacodynamic efficacy, but also how much of the drug enters
into the brain over a short time span. This is why street drugs are usually formulated in
ways allowing the users to smoke, snort, or intravenously inject them, and with these
introduction methods, effects on the brain can take place within half a minute. The shortterm and intensive pleasurable effects of stimulants are closely connected with the high
risk for abuse and dependence. Due to this connection, cocaine can induce powerful
dependent behaviors within the users.102-103

2.1.2 Physical and psychological dependence on cocaine
In general, addiction encompasses both physical and psychological dependence on
a substance. Physical reliance is characterized by the adaptive changes occurring within
the body in response to the chronic use of a drug. These changes mainly involve increasing
tolerance (i.e. a progressively increasing dose being required for the same effect).104-108 For
instance, if a long-term or heavy user of cocaine either cuts down or quits taking the drug,
physical reliance typically manifests through intense withdrawal reactions (e.g., depression,
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diarrhea, tremors, sleeplessness, and sweating) and drug craving. These symptoms are
often intolerable, and in the case of untreated or uncontrolled depression, are considered a
danger associated with an increased risk of suicide for cocaine addicts admitted to
treatment.109-111 Although there are currently no FDA-approved medications specific for
the treatment of cocaine withdrawal, some medications listed in the Table 2.1 have been
used to alleviate the withdrawal symptoms, but only during the period of cocaine
detoxication.112-114 In addition, some research also has shown that propranolol,115-118
buprenorphine,119-120 and naltrexone121 might be beneficial for those suffering from cocaine
withdrawal.

Table 2.1 Treatment options for cocaine detox withdrawal symptoms
Medicine

Notes

Gabapentin

A medication prescribed for prevention of seizures. This drug helps to
recover feelings of wellbeing by encouraging the release of the GABA.

Modafinil

A medication prescribed to alleviate the fatigue associated with cocaine
withdrawal by helping healthy nighttime sleep and increasing dopamine
production.

Topiramate

A medication prescribed to ease agitation by decreasing activity in the
central nervous system.

Vigabatrin

This drug may alleviate cocaine cravings by encouraging production of
GABA.

Baclofen

A medicine prescribed as a muscle relaxant. Baclofen may be utilized to
induce the release of GABA in cocaine recovery.

Treatment for psychological dependence on cocaine begins when physical reliance
on the drug is addressed by the medically supervised process of cocaine detoxification,
allowing the patient’s body to re-adjust to the absence of cocaine. Psychological reliance
10

on a drug is generally defined as a compulsive or perceived need for drug use and is
characterized by continual use of a substance without increasing tolerance or the
withdrawal symptoms resulting from physical dependence on a drug. In fact, in case of
cocaine addition, the developed habitual is driven more by the psychological addiction on
the drug than the physical withdrawal symptoms. Research from animal studies and human
trials have shown that an intense psychological craving for cocaine is caused by the
adaptive changes occurring within the brain due to the continuous presence of the drug.122
It has been observed that cocaine affects multiple major neurotransmitter receptor systems
in the central nervous system (CNS) including the dopaminergic neurotransmission system.

Table 2.2 The reported neurochemical differences between cocaine addicts and healthy
individuals
Neurotransmitter
system

Component

Serotonergic
neurotransmission

123-126

Decreased availability on cell surface

127-129

VMAT2*

Decreased availability

130-132

5-HT transporter

Increased expression

133

Increased levels

134

Decreased availability

135

Decreased glutamate levels

136

Decreased baseline GABA levels

137

D2 receptor

Extracellular 5-HT
5-HT18 receptor

Glutamatergic
neurotransmission
GABA
neurotransmission

Ref.

Increased cell surface availability

Dopamine transporter
Dopaminergic
neurotransmission

Difference compared to healthy
individuals

Glutamate/creatine ratio

GABA

* VMAT2: Vesicular monoamine transporter type 2

2.1.3 Effect of cocaine on dopaminergic neurotransmission
Dopamine is a major neurotransmitter responsible for regulating pleasurable
11

feelings and the reward system in the brain.82, 138-141 Once cocaine molecules accumulate
in the brain, they proceed to preserve high dopamine levels in the synapse and consequently
induce more intense signaling.142 It is generally believed by scientists that this intensified
dopaminergic neurotransmission is directly involved in the pleasurable feelings produced
by cocaine.
Importantly, it was demonstrated that there is a frightening trade-off associated with
the artificially elevated levels of dopamine in the reward circuits of the brain. Artificially
raising dopamine leads to significant changes in the expression of the genes related to
dopaminergic neurotransmission, leading to a reduced sensitivity of the dopaminergic
reward system to dopamine. Examples of such altered gene expression include the
increased cell surface expression of dopamine transporter (DAT) which increases the flux
of dopamine through the cell,143 and the downregulation of dopamine receptors.122 It was
also observed that bringing the changed dopaminergic function back to pre-abuse levels is
a very slow process, usually requiring at least a month.143 As cocaine wears off, fewer
dopamine molecules than usual are available in the synapse for signaling due to the
accelerated rate of dopamine re-uptake by the previously mentioned increase of cell surface
DATs. This substantial reduction in dopamine levels quickly ends the euphoric state and
results in craving and intense emotional stress. For example, when the euphoric state ends
in drug users, they typically begin to feel empty and may suffer from anxiousness,
restlessness, and agitation. This prompts them seek out cocaine to relax or re-achieve the
euphoric state. However, this seeking of cocaine may prove fruitless, largely due to the
decreased sensitivity of the dopaminergic system.
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2.1.4 Relapse
Relapse is considered the most refractory aspect of substance addiction.144 Relapse
means that a drug-addicted individual makes a conscious decision to abandon his/her
recovery plan and return to drug use. The National Institute on Drug Abuse (NIDA) has
estimated that approximately 50% of recovering drug addicts undergo relapse. Relapse can
occur unexpectedly, but it is typically brought on by triggers. Drug craving is regarded as
the main trigger for relapse, which can be triggered by positive reinforcement (i.e., an
increased desire to use drug due to its euphoric effects), negative reinforcement (i.e., an
increased desire to use drug to alleviate withdrawal symptoms), or environment factors,
such as being exposed to stress and drug-related stimuli.145 Therefore, the main goals of
relapse prevention for the drug addicts are to understand the issue of relapse and to learn
how to prevent or manage its occurrence during drug rehabilitation.146
Technically, drug craving by cocaine-addicts is more attributed to their
psychological addiction to the drug.83 Unfortunately, there are no currently FDA-approved
drugs that can specifically treat or manage mental reliance on cocaine. Along with this
scarcity of treatment options, the priming effect of cocaine makes it even more difficult to
treat cocaine addiction. Exposure to a single dose of cocaine can greatly intensify drug
craving behavior and eventually lead to full-blown relapse, no matter how many years of
abstinence the patients have achieved.147-148 It was also observed that the re-use of cocaine
after abstinence sharply increases the risk of cocaine overdose in the cocaine-addicted
patients due to their reduced tolerance to the drug with duration of abstinence.149
Considering that cocaine addicts admitted to treatment are still very vulnerable to the
temptation to relapse, they should be safeguarded against any exposure to cocaine; not only
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to prevent cocaine-primed relapse, but also to protect them against acute cocaine
intoxication which potentially happens on their journey from addiction to recovery.

2.1.5 Specific goals to be achieved for treatment of substance abuse disorder
Technically speaking, there are specific goals to be achieved for treatment of
substance abuse disorder.148 First, withdrawal symptoms should be properly addressed
during detoxication process. Second, drug craving needs to be prevented and properly
managed. Third, any physiological functions that are affected by drug use (e.g. the function
of the brain’s communication system) must be nurtured back to a more normal state. Finally,
and most importantly, the stimulant effects of a drug of abuse must be antagonized during
addiction recovery process.
However, in reality, it may be impractical to expect that all of these requirements
for addiction treatment can be accomplished separately. Since cocaine addicts admitted to
treatment are susceptible to the temptation to relapse, the lack of treatment options for drug
craving may make it difficult to successfully complete a painful and time-consuming
process of physiological re-adaptation to the absence of cocaine. As mentioned above, the
repeated use of cocaine leads to the adaptive changes related to a state of abnormal
physiological functioning in the user’s body and brain, which makes a major contribution
to drug carving behavior. Therefore, to achieve a better outcome in the treatment of cocaine
addiction, it seems necessary to first completely block the physiological effects of cocaine
in the body so that the reinforcing action of the drug can be decreased for a sufficiently
long period of time required to achieve long-term extinction of the drug-craving behavior.
For the treatment of cocaine abuse, considerable research effort has been focused
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on development of pharmacological agents which target the major neurotransmitter
transporter/receptor systems affected by cocaine (e.g. dopaminergic, GABAergic,
serotonergic, and glutamatergic systems).148, 150-151

Table 2.3 Drugs in phase II clinical trials for cocaine addiction
Neurotransmitter system

Name

Ref.

Amphetamine

152-154

Modafinil

121, 155-160

Ropinirole

161-163

Levodopa

155, 163

Aripiprazole

164-167

Topiramate

167-174

Baclofen

175-176

Doxazosin

177-179

Propranolol

180-183

Dopaminergic drugs

Glutamate/GABA drugs
Noradrenergic drugs

Although phase II clinical trials using the therapeutic compounds above have
produced promising results, over the last three decades, the traditional pharmacological
approaches for cocaine addiction treatment have not yet yielded a single treatment which
is both safe in human use and effective for treatment. This difficulty is mainly due to several
reasons as follows.149,

151, 184

First, the target-based, therapeutic small molecules are

designed to act at the sites of action of cocaine to antagonize the effects of the drug.
However, given that cocaine affects multiple neuromodulatory systems in the CNS,
targeting just one or several neurotransmitter systems for treatment might not be enough
for actual recovery from cocaine addiction. In addition, the current limited understanding
of the neuropharmacological mechanisms influenced by the stimulant action of cocaine
15

makes it more difficult to antagonize the effects of the drug. Second, many therapeutic lead
compounds for possible treatments of cocaine addiction have safety issues mainly due to
their high abuse potential. Due to the mechanism of these drugs targeting neurocommunication system, they generally risk the possibility of being abused. Third, many
drug candidates in clinical trials have displayed inappropriate pharmacokinetic properties
for human use although they have proven very effective in preclinical studies.

2.1.6 Pharmacokinetic approach for cocaine abuse treatment
In view of these difficulties, a new treatment strategy that directly targets and
inactivates cocaine has received increasing clinical attention.82 This pharmacokinetic (PK)
strategy aims to keep cocaine below its threshold concentration required to induce any
physiological effect at its sites of action. Indeed, this anti-cocaine effect is expected to be
beneficial in three clinical contexts. First, the chance of acute cocaine intoxication may be
substantially decreased or completely prevented due to the altered distribution of cocaine
and the acceleration of its clearance. Second, the cocaine-addicted patients on an effective
anti-cocaine treatment may also be protected from experiencing the reinforcing effects of
cocaine, which are required to reduce the chances of relapse primed by cocaine.
Considering the long-term anti-cocaine effect, the patients would also have a better
opportunity to naturally recover their damaged neuromodulatory systems. Third, long-term
cocaine abstinence achieved by the PK strategy might also facilitate the physiological readaptation to the absence of the drug by preventing cocaine actions in peripheral tissues.
Pharmacokinetic approaches for cocaine addiction treatment can be achieved by
either using a cocaine-specific antibody or through an efficient cocaine-hydrolyzing
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enzyme. In general, these protein-based PK agents are not expected to result in the same
side effects seen with therapeutic small molecules targeting the neurotransmitter
transporter/receptor systems in the CNS. This is because they barely cross the BBB to reach
the CNS. Both types of PK agents have proven effective for preventing the rapid
distribution of cocaine molecules into the CNS after drug intake in both pre-clinical and
clinical studies.185-189 However, using an efficient cocaine-hydrolyzing enzyme has a
theoretical, but critical, advantage over antibody-based approaches (active and passive
immunization) in that it would be very difficult for the cocaine-addicted patients to increase
drug intake sufficient to overwhelm the therapeutic effect of efficient cocaine-hydrolyzing
enzyme. This is in contrast to the therapeutic antibodies which could be possibly saturated
by cocaine molecules allowing most of the drug to remain free and available for action.

2.1.7 Enzyme-based therapy for cocaine abuse
In our previous studies, we (our lab at the University of Kentucky) have designed
and discovered high-activity butyrylcholinesterase (BChE) mutants, also known as cocaine
hydrolases (CocHs), that can rapidly convert naturally occurring, biologically active (–)cocaine to physiologically inactive metabolites ecgonine methyl ester (EME) and benzoic
acid. In particular, the first one of our designed CocHs (denoted as CocH1), i.e. the
A199S/S287G/A328W/Y332G mutant, demonstrated a ~1000-fold improved catalytic
efficiency against (–)-cocaine compared with the wild-type BChE (kcat = 4.1 min− 1 and KM
= 4.5 µM)190-191 and an effectiveness as an enzyme or gene therapy for cocaine abuse
treatment without significant adverse effects in animal experiments.192-195

17

Figure 2.1 Cocaine metabolic pathways in physiological condition.196-197

Further, CocH1 truncated after amino acid 529 was fused with human serum
albumin (HSA) to prolong the biological half-life without changing the catalytic activity
of CocH1 against cocaine.198 The HSA-fused CocH1 (known as Albu-CocH, Albu-CocH1,
AlbuBChE or TV-1380 in the literature) has been proven safe and promising for use in
animals and humans in preclinical and clinical studies.84, 199 However, its actual therapeutic
value for cocaine addiction treatment is limited by an insufficiently long biological halflife (~8 h in rats 198 or 43-77 h in humans84). Recently, a Phase II clinical trial of TV-1380
for cocaine addiction treatment did not show statistically significant efficacy with the once18

weekly dosing schedule due to its relatively short biological half-life.85 Nevertheless, it has
been concluded that “Although the continued development of TV-1380 appears unlikely, its
promising clinical profile should embolden efforts to develop new enzyme products that are
capable of delivering greater catabolic activity”85 in order to be effective with the desirable
once-weekly dosing schedule for cocaine addiction treatment. Our most recently reported
studies in various animal models of cocaine overdose treatment show that Albu-CocH1 (or
TV-1380) itself would be more appropriate for cocaine overdose treatment.200-201

2.2 The focuses of this research
In order to meet the requirements to be an effective enzyme therapeutic for
cocaine addiction, CocH1 has further engineered so that the next generation of CocHs
have even higher catalytic activity compared to that of CocH1 and, more importantly,
have a sufficiently long biological half-life for human cocaine addiction treatment.
Indeed, a growing body of preclinical data including our animal study results have shown
that the catalytic efficiency of a cocaine-metabolizing enzyme is a major factor
determining the efficacy in protecting animals against acute cocaine intoxication and
reinstatement (equivalent to relapse within humans) provoked by the cocaine priming
effect. Therefore, to deliver greater catabolic activity to human body, our research group
has made effort on development of the next generation of CocHs whose cocainehydrolyzing activities are substantially higher than that of CocH1 (Table 2.4). At the same
time, for the same reason, CocHs whose biological half-lives are sufficiently long for
human cocaine addiction treatment are currently under development. In this chapter, I
described our efforts to develop novel CocH entities with a prolonged duration of action.
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Table 2.4 The new generation of CocHs with an improved catalytic efficiency against
cocaine
a

Relative catalytic efficiency (kcat/KM).
kcat

KM
(min ) (µM)

Enzyme

−1

BChE wt

RCEa

Ref.

4.1

4.5

1

CocH1 (A199S/S287G/A328W/Y332G)

3060

3.1

1080

190

CocH2 (A199S/F227A/S287G/A328W/E441D)

1730

1.1

1800

202

CocH3 (A199S/F227A/S287G/A328W/Y332G)
CocH5
(A199S/F227A/P285A/S287G/A328W/Y332G)

5700

3.1

2020

203

14600

3.7

4400

204

3.1

US
5500 Patent #
9365841

CocH6
(A199S/F227S/P285Q/S287G/A328W/Y332G)

15500

2.3 Results & Discussion
2.3.1 Insights from molecular modeling
Molecular modeling studies were performed in our lab to study how neonatal Fc
receptor (FcRn) binding with human IgG1 Fc variants205 and the corresponding fusion
proteins. Through the modeling studies, the relative binding affinities of various fusion
proteins with the FcRn at pH 6 were estimated. Based on the computationally estimated
binding affinities, several Fc variants, including Fc(3m), Fc(4m), and Fc(6m) (as indicated
below), were predicted to have significantly improved binding affinities with the FcRn.
Hence, the experimental studies described below were focused on these Fc variants.
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2.3.2 Characterization of CocH3-fused with human IgG1 Fc variants
Altered binding to FcRn can lead to significant changes in the biological half-lives
of therapeutic protein drugs (e.g. therapeutic antibodies, and HSA- or Fc-fused biotherapeutics) in both humans and animals. Therefore, it is interesting to characterize their
binding affinities with FcRn from clinically relevant species (human, monkey, rat, and
mouse). This in vitro analysis helps predict whether positive results obtained from the
pharmacokinetic studies in animal models can be translated and applied when utilized in
human clinical trials.
In this study, we generated a comprehensive data set on the binding of Fc-fused
CocH3 proteins with FcRn proteins from four different species (human, monkey, rat, and
mouse) and these results can be utilized to predict whether the increased FcRn binding
affinity of CocH3 translates to pharmacokinetic benefit in nonhuman primates or humans.

2.3.2.1 Design and expression of FcRn as a single-chain like fusion protein
The neonatal Fc receptor (FcRn) was first discovered as the receptor which is
responsible for the transfer of maternal Immunoglobulin Gs (IgGs) from breast milk to
babies across their intestinal epithelial cells. FcRn also enables maternal IgGs to cross the
materno-fetal barrier during pregnancy.206 This cell surface protein consists of two protein
subunits, a transmembrane alpha chain (denoted as heavy chain for convenience) and a
beta 2 microglobulin (B2M), these subunits non-covalently interact with each other at a
1:1 molar ratio. Currently, FcRn has received increased clinical attention because of its
pivotal role in regulating the homeostasis of IgG and albumin in mammals through its
distinctive pH-dependent physical interaction with specific serum proteins. Indeed, the Fc
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region of IgG or albumin strongly interacts with FcRn at a slightly acidic condition, but the
formed complex is easily dissociated at the physiological pH.207 With the help of this
unique binding feature of FcRn, the IgG and albumin captured in endosomes can escape
from cellular endolysosomal degradation and eventually be returned to the circulatory
system for reuse.208-210 In functional FcRn-deficient (β2m -/-) mice, it was observed that
both the serum half-life and endogenous level of IgG substantially decrease by a factor of
about 6 and 10, respectively,211 and the lifespan of albumin also shortened significantly.212213

This clearly indicates the importance of FcRn for the long serum persistence of both

IgG and albumin. Added to this, many studies have shown that this specific function of
FcRn is well conserved across different species including human,214 monkey,215-217 rat,218
mice,211, 219-220 and even chickens.221
Currently, there is a large market pressure for a treatment that both improves patient
convenience and compliance via a less frequent dosing schedule of a therapeutic protein
drug.77 Because enhanced binding affinity to FcRn at a certain range can greatly improve
the pharmacokinetic profile and therapeutic efficacy of a protein drug,56-57 much of the
research effort has been spent on the engineering of these protein drugs (e.g. therapeutic
antibodies and HSA- or Fc-fused bio-therapeutics) to increase their FcRn binding affinities.
However, these attempts were limited due to the difficulty of obtaining the required amount
of functional FcRn proteins for use in the binding affinity assays.
Many different methods have been employed for the large-scale production of
soluble functional FcRn. In previous studies, two genes encoding each of the different
subunits of FcRn, a C-terminal transmembrane domain truncated heavy chain variant and
the wild-type B2M, were frequently co-expressed in mammalian or insect cells and the
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resultant heterodimer complexes secreted into the culture medium were then purified.77, 214,
220

This type of soluble FcRn protein was proven fully functional in binding to antibody or

albumin, and have been widely used to improve our understanding of FcRn itself and its
interaction with IgG or albumin. However, there is an unresolved issue in this approach.
The heavy chain variant is not as strongly expressed in both insect and mammalian systems,
whereas B2M is highly produced, which restricts the overall production yield of functional
FcRn. As an alternative approach to the large-scale production of soluble FcRn, the
receptor was also expressed in Pichia pastoris (a species of yeast),222 and E. coli.223
However, against all expectations, the FcRn protein expressed in Pichia pastoris was not
glycosylated and E. coli-derived FcRn proteins formed inclusion bodies in the
cytoplasm.209, 224
Recently, it was reported by Yang Feng et. al. that soluble, fully-functional human
FcRn can be expressed in mammalian cells as a single fusion protein.206 The B2M was
genetically conjugated to the N-terminus of the transmembrane domain truncated heavy
chain variant through a short amino acid linker. The generated soluble single-chain FcRn
(sFcRn) was not only highly expressed in mammalian cells, but also could be easily
purified through simple affinity chromatography via its C-terminal hexa-histidine tag. In
addition, the purified sFcRn proteins were also fully functional.
Inspired by the design of the soluble human FcRn reported by Yang Feng et. al.,206
multi-species FcRn proteins (human, monkey, rat, and mouse) were designed to be
expressed as a soluble single-chain protein in the present study. The designed sFcRn genes
were expressed and purified as described below. As shown in Fig. 2.2, the N-terminal
sequence for the leader peptide of B2M was first replaced with the leader peptide sequence
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of mouse Ig kappa-chain to facilitate the secretion of the fusion proteins from the cytosol
to the extracellular space. Both the signal peptide and transmembrane domain of the
corresponding heavy chain were excluded from the design of the new fusion genes. Then,
a mature B2M sequence was genetically conjugated to the N-terminus of the mature
sequence of its corresponding heavy chain via a flexible amino acid linker ((GGGGS)3). A
hexa-histidine tag (Hisx6) was introduced at the C-terminal end of all the fusion gene when
they were synthesized by GenScript to simplify the protein purification process.

Figure 2.2 Schematic presentation of the soluble single-chain FcRn proteins of different
species.
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Each fusion gene was cloned into a mammalian expression vector, pCMV-MCS.
The fusion proteins were expressed in 293 FreeStyle cells (293FS), an engineered HEK293
cell-line, and then purified by immobilized metal ion affinity chromatography.

2.3.2.2 Preparation of Fc-fused CocH3 proteins
For the extension of biological half-life, CocH3 truncated after amino acid 529 was
fused with either the wild-type Fc region of human IgG1 (i.e. CocH3-Fc) or the IgG1-Fc
variants (i.e. CocH3-Fc(v)) that we designed. (Fig. 2.2) These proteins were expressed and
purified as described below.

Figure 2.3 Schematic presentation of the newly designed Fc-fused CocH3 proteins.

2.3.2.3 Binding affinity of Fc-fused CocH3 toward different FcRn
To identify the Fc-fused CocH3’s increased binding affinity toward human FcRn,
and to examine whether the selected enzyme also shows increased binding affinity for FcRn
25

of other preclinical species (monkey, rat, and mouse), we investigated the interaction of
different Fc-fused CocH3 proteins with these FcRn proteins. The FcRn binding was
analyzed by ELISA. Results are summarized in Table 2.5. The determined KD value of
CocH3-Fc toward human FcRn is in good agreement with the values determined by others
for the binding of the wild-type human IgG1.75, 225
As

expected,

the

six

amino

acid

substitutions

(A1V/M38Y/S40T/T42E/D142E/L144M) introduced into the Fc portion of CocH3-Fc
greatly increased the affinity of the fusion protein toward human and monkey FcRn at pH
6.0, approximately 48- and 45-fold, respectively. However, the same increase in affinity was
not seen toward mouse FcRn with only a 9-fold increase. It is likely that this difference is
mainly attributed to the innate high affinity of human Fc to mouse FcRn. Interestingly, it was
also observed that the affinities for the binding of Fc-fused CocH3 proteins to monkey FcRn
are almost the same as with human FcRn, which strongly suggests that all the newly designed
six residues interact with human and monkey FcRn at pH 6.0 in a very similar manner.
In addition, we observed that none of the CocH3-Fc(v) proteins have higher binding
affinity for rat FcRn than CocH3-Fc. However, CocH3-Fc(4m) and CocH3-Fc(6m) show
significantly increased affinity for rat FcRn, compared with CocH3-Fc with
A1V/D142E/L144M (i.e. CocH3-Fc(3m)). These results suggest that the introduction of
A1V/D142E/L144M into the Fc portion negatively affects the binding of CocH3-Fc to rat
FcRn at pH 6.0. Indeed, previous reports already show that rat FcRn has strong binding
affinity at pH 6.0 for different subclasses of human IgG including IgG1 and IgG2 (KD =35
and 20 nM, respectively)216, 226 and rat FcRn retains significant binding with human IgG1
even at neutral pH (KD =1389 nM).226
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Table 2.5 Summary of determined equilibrium dissociation constants (KD) of interaction of
Fc-fused CocHs with FcRn (at pH 6.0, (nM))

Fc-fused
CocH3

Neonatal Fc receptor (FcRn)
Human

Monkey

Rat

Mouse

CocH3-Fc(wt)

~ 2500

~ 2500

37.46 ± 7.07

95.65 ± 13.22

CocH3-Fc(3m)

991.6 ± 24.7

1004 ± 165

159.40 ± 6.40

50.73 ± 10.25

CocH3-Fc(4m)

326.9 ± 14.6

325.2 ± 18.6

61.29 ± 6.90

11.96 ± 2.62

CocH3-Fc(6m)

52.14 ± 3.54

56.65 ± 5.09

50.74 ± 4.89

10.06 ± 1.55

Results are representative of three independent experiments and each experiment was
performed as triplicate. The values are expressed as mean ± S.D.

2.3.3 Determination of biological half-life in rats
To examine whether enhanced binding affinity at pH 6 for FcRn improves the
biological half-life of Fc-fused CocH3, a pharmacokinetic (PK) study was carried out in rats
(Rattus norvegicus). The in vivo data were based on intravenous (i.v.) injection of the
enzymes in the tested animal model. The generated PK data are depicted in Fig. 2.4 and the
biological half-lives obtained are summarized in Table 2.6. The results clearly show that the
fusion proteins of the truncated CocH3 (without the tetramerization domain) to the Nterminus of the Fc portion of IgG1 have substantially longer biological half-lives (up to ~200
h) than that (~7 h) of the full-length CocH3, denoted as CocH3 in Fig. 2.4. Among the Fcfused CocH3 proteins tested here, CocH3-Fc with A1V/M38Y/D142E/L144M (i.e. CocH3Fc(4m)) displays the longest biological half-life (∼200 h) in rats and the introduction of these
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four mutations increases the biological half-life of CocH3-Fc more than 2-fold. CocH3Fc(6m) also has a long biological half-life comparable to that of CocH3-Fc(4m), but the
A1V/D142E/L144M mutations of Fc(4m) extend the biological half-life of CocH3-Fc only
by ∼23 h, suggesting that the M38Y on the Fc region plays a critical role in interaction with

rat FcRn at pH 6.0.

Intriguingly, it was also observed that CocH3-Fc does not show the longest biological
half-life despite of its strongest rat FcRn binding affinity, which suggests that some other
factors such as the delayed release of CocH3-Fc at neutral pH or its relatively low thermal
stability might have negative effects on the serum persistence of CocH3-Fc in rats. Indeed,
it was previously reported that extended serum persistence of human IgG due to the
benefits of increased FcRn binding at pH 6.0 can be offset by increasing neutral pH FcRn
affinity in rats.75
Considering that CocH3-Fc(6m) rather than CocH3-Fc(4m) shows substantially
higher binding affinity toward both human and monkey FcRn, there may be a good
possibility that CocH3-Fc(6m) has a much longer biological half-life in a following animal
study using monkeys and human clinical trials, compared to CocH3-Fc(4m).
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Figure 2.4 Serum concentration (%) versus time profiles of Fc-fused CocH3 proteins in rats.
All enzymes were administered via i.v. infusion at 0.06 mg/kg body weight and the serum
concentrations of Fc-fused CocH3 were determined by a sensitive radiometric assay using
[3H](−)-cocaine. Results are shown as mean ± standard error. Other lab members (Ting
Zhang and Xirong Zheng et al.) kindly provided the data for this figure.
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Table 2.6 The determined distribution and biological half-lives of Fc-fused CocH3 proteins
in rats in comparison with the unfused CocH3 in rats. The parameters were obtained from
fitting to the well-known double-exponential equation227 by GraphPad Prism 7.04:
( [ E ]t = Ae − k1t + Be − k2t ) which accounts for both the enzyme distribution process (the fast
phase, associated with k1) and elimination process (the slow phase, associated with k2). The
half-life (t1/2) associated with the enzyme elimination rate constant k2 is known as the
elimination half-life or biological half-life.
Protein

Distribution t1/2 (hr)

Biological t1/2 (hr)

CocH3

0.2

7

CocH3-Fc(wt)

4.9

85

CocH3-Fc(3m)

6.4

107

CocH3-Fc(4m)

23

218

CocH3-Fc(6m)

35

222

2.3.4 Effectiveness of CocH3-Fc(3m) in blocking the striatal dopamine transporter
trafficking induced by cocaine
Dopamine is a monoaminergic neurotransmitter which mediates a number of brain
activities including reward, emotion, learning, and motivation.228 The dopamine transporter
(DAT) is a key determinant of the level of synaptic dopamine. DAT pumps excess
dopamine molecules from the synaptic cleft back into presynaptic neurons when it is
expressed on their cell surface, and in turn terminates the signal of the neurotransmitter.229
It has been demonstrated that different DAT substrates or inhibitors such as cocaine
facilitate the translocation of DAT from cytosol to cell surface for an increased function.
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The altered surface expression or malfunction of human DAT (hDAT) is well-known to be
a major cause of psychiatric and neurological disorders such as clinical depression, bipolar
disorder, and substance use disorder, also known as drug addiction,230-231 thus hDAT has
been a clinically valuable target for the treatment of these serious brain diseases.232-234
Cocaine is believed to produce the feeling of euphoria by primarily inhibiting DAT
in the central nervous system. Many pre-clinical and clinical studies have shown how
altered DAT function contributes to substance use disorder. For example, exposure of brain
to a psychoactive stimulant like cocaine leads to a rapid increase in the extracellular fluid
(ECF) levels of dopamine235-237 and in turn increases in the reuptake of dopamine.238-239
These immediate effects of cocaine on the brain consequently cause the reduction of
sensitivity of the brain to dopaminergic neurotransmission, which contributes to the drug
craving. Indeed, the facilitated dopamine reuptake after exposure to cocaine is mainly
attributed to the increasing cell surface expression of DAT and cocaine is proven to rapidly
and strongly induce the trafficking of dopamine to cell surface in both DAT expressing
cells and brain.128, 240-242 In addition, it has been observed that the changed dopaminergic
neurotransmission especially in the specific brain regions related to the reward circuits (e.g.
striatum and nucleus accumbens) is more closely associated with drug abuse potential.141,
243-244

To exam whether the pretreatment of rats with 3 mg/kg CocH3-Fc(3m) (i.v.) before
the i.p. administration of cocaine efficiently protects rats from the physiological effects of
the drug on the brain, we performed a DAT cell redistribution assay.
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Figure 2.5 The schematic presentation of DAT cellular distribution assay.

As shown in Fig. 2.6, most DAT proteins were observed in the non-biotinylated
faction of the striatal synaptosomes prepared from both the saline controls and the enzyme
control without the cocaine injection. Considering that synaptosomes are an isolated
synaptic terminal from a neuron, these findings implicate that the majority of DAT is
originally located within the intracellular space of synaptic neurons and the i.v.
administration of 3 mg/kg CocH3-Fc(3m) lead to no significant change in the subcellular
localization of the transporter. Importantly, it was also observed that the pretreatment of
CocH3-Fc(3m) (3 mg/kg i.v.) 3 min prior to a lethal dose of cocaine (60 mg/kg i.p.) not
only saves all the rats tested from acute cocaine intoxication, but also completely blocks
the DAT trafficking-induced by the lethal cocaine dose. This may indicate that the
accelerated cocaine clearance achieved by the enzyme is able to suppress cocaine below
its threshold concentration in the body (0.22±0.07 µM) required to elicit physiological
effects.245
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Figure 2.6 The cell surface distribution of dopamine transporter (DAT) in the striatum of
adult rats. Saline or 3 mg/kg CocH3-Fc(3m) was injected i.v. in rats (n = 4), 3 min before
i.p. administration of a dose of cocaine (60 mg/kg). Representative blots for DAT
distribution between biotinylated (Biotin; cell surface) and non-biotinylated (Non-biotin;
intracellular) fractions in striatal synaptosomes from the rats. Na+/K+ ATPase and
demethylated-phosphatase A (demethylated-PP2A-C) were used as a marker for membrane
protein and cytosolic fraction, respectively. These markers were served to ascertain the
biotinylation efficiency of surface proteins whereas β-actin was used as a loading control.
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2.4 Experimental details
2.4.1 Materials & Animals
(−)-Cocaine was kindly provided by the National Institute on Drug Abuse (NIDA)
Drug Supply Program (Bethesda, MD) and radioactive [3H](−)-Cocaine was obtained from
PerkinElmer (Waltham, Massachusetts). All other chemicals were ordered from SigmaAldrich (St. Louis, MO) and Thermo Fisher Scientific (Waltham, MA). Male SpragueDawley rats (220–250 g) were purchased from Harlan (Harlan, Indianapolis, IN). All the
animal experiments were performed in a same colony room in accordance with the Guide
for the Care and Use of Laboratory Animals as adopted and promulgated by the National
Institutes of Health. The animal protocol was approved by the IACUC (Institutional Animal
Care and Use Committee) at the University of Kentucky.

2.4.2 Construction of gene expression plasmids
For recombinant lentiviral packaging to generate stable cell lines expressing the
gene of interest, the C-terminal of truncated CocHs were first genetically fused to the Nterminal of the Fc portion of wild-type human IgG, a Fc variant, or the wild-type HSA by
overlapping extension PCR with Phusion DNA polymerase. Then, the PCR products were
digested with restriction endonucleases Hind III and XbaI. The gel purified PCR products
were then ligated to the pCSC lentiviral vector using T4 DNA ligase. The resulting DNA
constructs were used for the following recombinant lentiviral packing experiment (2.4.3).

2.4.3 A recombinant lentiviral packaging system for stable cell generation
To package the recombinant lentivirus particles carrying the gene of Fc- or HSA35

fused CocH3, 293FS cells were cultured and prepared in DMEM medium containing 10%
Fetal Bovine Serum (FBS) (Life Technologies). When the cell reached 70% confluence, a
lentivirus plasmid encoding the gene of interest was transfected into the cell with the two
packaging vectors (pMDLg/pRRE and pRSV-Rev) and one envelope plasmid (pCMVVSV-G) by lipofection at a mass ratio of 10:6.5:2.5:3.5. For transfection of 293FS cells in
a 10 cm dish, those DNA plasmids (approximately 22.5 µg in total) were first mixed with
1 ml of Opti-MEM® (Life Technologies) without serum. 25 µl of the TransIT-PRO
Transfection Kit (Mirus Bio LLC, Madison, WI) was then gently mixed with the medium
followed by incubation at RT for 10 min. The transfection complex was carefully added to
the cell in a dropwise manner and the cells were incubated at 3% CO2 at 37°C. 16 h after
transfection, the culture medium with exchanged with a fresh complete medium. From this
point, the culture medium was replaced with a fresh complete medium and collected every
following 24 h for three days. The collected media were then filtered through a 0.45-µm
cellulose acetate filter followed by ultra-centrifugation in Beckman SW28 rotor at 800,000
× g for 1.5 h at 4°C to obtain the pellet of the recombinant lentiviral particles. The resulting
pellet were then suspended in Hank’s balanced salt solution and freshly utilized for
generation of stable CHO-S cells. The lentivirus titration was performed using
QuickTiterTM lentivirus rapid quantitation kit (Cell Biolabs, San Diego, CA).

2.4.4 Transient expression and purification of soluble single-chain FcRn (sFcRn)
The DNA sequences of the beta 2 microglobulin chain (B2M) and heavy chain
(AKA, Fc fragment of IgG receptor and transporter) of FcRn are based on the reported
sequences in the GenBank database (National Center for Biotechnology Information)

36

(Table 2.4) and codons were optimized for expression in HEK293 cells.

Table 2.7 The referred DNA sequences for FcRn expression
Species (Binomial name)

B2M

heavy chain

Human (homo sapiens)

NM_004048

NM_004107

Monkey (Macaca fascicularis)

NM_001284689

NM_001284551

Rat (Rattus norvegicus)

NM_012512

NM_033351

Mouse (Mus musculus)

NM_009735

NM_010189

FcRn proteins from clinically relevant species (human, monkey, rat, mouse) were
expressed as a single chain-like fusion protein. Briefly, the highly hydrophilic B2M was
genetically inked to a transmembrane domain truncated variant of the heavy chain via a
flexible amino acid linker as described in the Results and Discussion section (2.3.2.1). All
the newly designed fusion genes were synthesized by GenScript to facilitate the
purification of the proteins. Each fusion gene was cloned into a mammalian expression
vector, pCMV-MCS. 293 FreeStyle cells (293FS) (Life Technologies), an engineered
HEK293 cell-line, were incubated in (serum-free) FreeStyle 293 Expression Medium (Life
Technologies) at 37°C in a humidified atmosphere with 8% CO2 and transfected with gene
expression DNA constructs encoding the protein of interest using the TransIT-PRO
Transfection Kit (Mirus Bio LLC, Madison, WI)) when the number of the cells reached 1.5
× 106 cells/mL. The culture medium was harvested 6 days after transfection. The FcRn
protein secreted into the culture medium was purified by Immobilized Cobalt Affinity
Chromatography (ICAC). After removing cells by centrifugation, the cell-free culture
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medium was mixed with rmp HisPur Cobalt Resin (Thermo Fisher Scientific) preequilibrated with 20 mM Tris⋅HCl, pH 7.4, containing 200 mM NaCl and incubated for
overnight at 6°C with occasional stirring. Then, the suspension was packed in a column
and washed with 10 column volume (CV) of Washing buffer (20 mM Tris⋅HCl, pH 7.4,
containing 20 mM imidazole and 200 mM NaCl) until an OD280 < 0.02 was achieved; then
the resin-bound proteins were eluted by Elution buffer (20 mM Tris⋅HCl, pH 7.4,
containing 200 mM imidazole and 200 mM NaCl). The eluate was then dialyzed in storage
buffer (50 mM Hepes, 20% sorbitol, 1 M glycine, pH 7.4) by Millipore Centrifugal Filter
Units. The entire purification process was conducted on ice and the purified FcRn proteins
were stored at −20°C until use. Their purity was analyzed by SDS-PAGE on a 4−12%
NuPAGE Novex Bis-Tris gel (Life Technologies).

2.4.5 Large-scale protein expression and purification of Fc-fused CocHs
For the scaled-up preparation of Fc-fused and HSA-fused CocHs, FreeStyle™
CHO-S cells (CHO-S) (Life Technologies) were first infected with recombinant lentivirus
containing the gene of interest and then the transduced cells were resuspended and
incubated in FreeStyle CHO Expression Medium (Life Technologies) with 8 mM lglutamine (Life Technologies) at 37°C in a humidified atmosphere with 8% CO2. The day
before infection, the cells were seeded at a concentration of 0.5 × 105 viable cells/well in
12-well plate and stabilized in freestyle CHO expression medium containing 1% FBS and
8 mM L-glutamine and. In the presence of 1% FBS, CHO-S cells quickly attach to the
tissue culture plate. For successful lentiviral transduction, the recombinant lentiviral
particles harboring the gene of interest were incubated with the cells. Simultaneously,
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positive charged Polybrene (Santa Cruz Biotechnology) (1 µl/ml) was added into the cell
culture medium to improve the infection efficiency via neutralization of the electrical
charge repulsion between the cell surface and lentiviral particles. 24 h after transduction,
the medium was exchanged with a fresh medium and then incubated usually for 3 days for
complete recovery of the cells from the infection. The transduced cells were then suspended
by trypsinization and separated into two halves. One half was utilized for the next round
of transduction with the expectation of improved target protein expression via increasing
gene copy number of the protein of interest inside of the cells. The other half was used for
protein yield determination. After each infection, efficiencies of the achieved stable cell
pools were examined and the pool with the highest expression yield was chosen for scaledup production. For large-scale production, the selected cell pool was incubated in an
agitated bioreactor BioFlo/CelliGen 115 (Eppendorf). The cells were amplified at 37 °C in
shake flasks to the designated volume and density before they are transferred to a bioreactor.
The cells were seeded in a bioreaction at a concentration of 0.8 × 106 viable cells/ml. The
bioreactor was operated in a batch model and the temperature and pH of the cell culture
medium were kept at 7.4 and at 32 °C. 10 days after cell seeding, the culture medium was
harvested, and the enzymes were purified.
The Fc-fused CocH3 proteins secreted into the culture medium was purified by
protein A affinity chromatography. After removing cells by centrifugation, the cell-free
culture medium was mixed with rmp Protein A Sepharose Fast Flow (GE Healthcare Life
Sciences) pre-equilibrated with 20 mM Tris⋅HCl, pH 7.4, and incubated for overnight at
6°C with continual shaking. Then, the mixture was packed in a column and washed with 5
column volume (CV) of 20 mM Tris⋅HCl, pH 7.4, containing 200 mM NaCl until an OD280
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< 0.02 was achieved; then the protein was eluted by 50 mM sodium acetate, pH 4.0,
containing 200 mM NaCl. HSA-fused CocH1 was also expressed in the method described
above. Using the AlbuPure matrix (Prometic Life Sciences Inc., Laval, Canada), CocH1HSA was purified where the cell-free culture medium was loaded onto packed bed preequilibrated with 50 mM sodium acetate (pH 5.3), extensively washed with 8 CV of
equilibration buffer. Then, the resin bound protein was eluted with 5 CV of 50 mM
ammonium acetate, pH 7.4. For buffer exchange, the eluate was dialyzed in storage buffer
(50 mM Hepes, 20% sorbitol, 1 M glycine, pH 7.4) by Millipore Centrifugal Filter Units.
The entire purification process was performed in a cold room at 8°C and the purified
proteins were stored at −80°C until use.

2.4.6 Enzyme-linked immunosorbent assay (ELISA)
Binding of Fc-fused CocH3 to different FcRn proteins
400 ng of 6xHis-tagged schFcRn in 100 μl 0.05M PBS, pH 7.4, was immobilized
in a 96 well flat-bottomed EIA plate (Corning) at 4 °C overnight (or 37 °C for 2 h). At the
same time, corresponding empty wells without FcRn coating were left as a negative control.
The liquid was dumped from the plates and the rest was drained on paper towel. Coated
wells were blocked with blocking buffer (0.05M PBS, pH 6.0, containing 1 mg/ml casein)
(250 μL/well) at RT for 1 h. After washing twice with washing buffer (0.05M PBS, pH 6.0)
(250 μL/well), 100 μl of Fc fusion protein diluted in blocking buffer, pH 6.0 was added to
each well at a range of concentrations. The plate was then covered with an adhesive plastic
and incubated, with continual shaking, at RT for 1 h. After washing three times with
washing buffer, the HRP-conjugated antibody (anti-human IgG-Fc Ab-HRP) (70 μl/well),
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diluted with blocking buffer at a ratio of 1:20,000, was added into each well and incubated
at RT for 30 min on a shaker. The wells were then washed three times with washing buffer
(250 μl/well) before 250 μl TMB substrate was added to the wells. The ELISA plate was
kept in the dark until the desired color develops. The reaction was stopped with 100µL of
0.5M HCl. The absorbance (= the developed blue color) was measured at 450 nm using a
microplate reader. All measurements were performed in triplicate or quadruplicate.

2.4.7 Pharmacokinetic studies in rats
Rats were injected with Fc-fused CocH3 proteins through the tail vein at a dose of
0.06 mg/kg body weight for Albu-CocH1; and 0.06 mg/kg. Blood samples were then
obtained by needle puncture of the saphenous vein. Approximately 100 µL of blood was
collected into a heparin-treated capillary tube at differing time points after protein injection.
The plasma was separated from the collected blood samples by centrifugation (15 min, at
5,000 × g). The concentration of Fc-fused CocH3 in plasma was determined by a highly
sensitive radiometric assay as described in our previous report.246 The obtained PK data
(time dependent enzyme concentrations) ([E]t) were fitted to a double-exponential equation
247

by GraphPad Prism 5.01 software: [ E ]t = Ae − k1t + Be − k2t , which explains both the

distribution process (the fast phase, associated with k1) and the elimination process (the
slow phase, associated with k2) of the Fc-fused CocH3 protein in animals.
The t1/2 associated with the elimination rate constant k2 of the fusion protein is known as
the biological t1/2 or elimination t1/2.

41

2.4.8 DAT cellular distribution assay
All steps were performed on ice or at 4 °C.
Preparation of synaptosomal pellets
Striatum of one cocaine-treated and one vehicle-treated rat were homogenized in
individual tissue homogenizers, containing 3 ml of sucrose solution (0.32 M sucrose and 5
mM NaHCO3, pH 7.4). Synaptosomal suspensions were exposed to two centrifugation
steps (2,000g, 10 min, 4 °C followed by 20,000g, 17 min, 4 °C). The resulting pellets were
then resuspended in the sucrose solution.
Biotinylation of cell surface protein
Synaptosomal suspensions included about 250 µg protein for striatum.
Suspensions were then incubated (at 4 °C for 1 hr on a shaking) in 500 µl of 1.5 mg/ml
bifunctional cross-linker (sulfo-NHS biotin) in PBS/Ca/Mg buffer (2.7 mM KCl, 138 mM
NaCl, 0.1 mM CaCl2, 1.5 mM KH2PO4, 9.6 mM Na2HPO4, 1 mM MgCl2, pH 7.4), which
labels all the membrane proteins with biotin. Free sulfo-NHS biotin molecules were then
removed by centrifugation (8000g, 4 min, 4 °C), followed by washing with 1 ml of 100
mM glycine in PBS/Ca/Mg buffer. This washing step was repeated twice. Samples were
then centrifuged (8000g, 5 min, 4 °C) and washed twice with 1 ml of PBS/Ca/Mg buffer
with no glycine. The surface-biotinylated synaptosomes were then broken by sonication
for 5 seconds followed by incubation (at 4 °C for 20 min on a shaker) in Triton X-100
buffer (150 μl for striatal synaptosomes; 10 mM Tris, 150 mM NaCl, 1 mM EDTA, 1.0%
Triton X-100, 250 μM phenylmethysulfonyl fluoride, 1 μg/ml leupeptin, 1 μg/ml aprotinin,
1 μM pepstatin, pH 7.4). Lysates were then exposed to centrifugation (13,000g, 1 hr, 4 °C).
The resulting supernatants represent the total protein fraction.
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Isolation of biotinylated proteins
To separate the biotinylated cell surface proteins from the non-biotinylated
intracellular proteins, the supernatant was incubated with Avidin-coated beads at RT for 1
hr on a shaker, and then centrifuged (13,000g, 2 min, 4 °C). The resulting supernatant
represent the intracellular fraction. The Avidin-bound biotinylated proteins constituted the
cell surface fraction. The precipitated Avidin beads were washed five times with 1% TritonX-100 buffer. Then, the beads were boiled for 10 min in SDS-loading buffer to separate
the biotinylated cell surface proteins from the biotin- Avidin complex. Finally, the resulting
cell surface and intracellular fractions were stored at -20 °C until use for western blot
analysis.
Western blotting
Biotinylated and non-biotinylated fractions were subjected to gel electrophoresis.
Blots were then incubated, with continuous shaking, for 1 hr at RT with primary antibody
for DAT, followed by incubation with HRP-conjugated secondary antibody (30 min, RT).
DAT protein (72 kDa) was detected using chemiluminescence. Na+/K+ ATPase (a plasmamembrane enriched protein; 100 kDa) or demethylated PP2A-C (an intracellular protein;
34 kDa) were also detected on blots and these molecular markers served to ascertain the
efficiency of biotinylation of surface proteins. β-actin (a cytoskeletal protein; 42 kDa) was
used as an internal loading control.
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Chapter Ⅲ. Kinetic Characterization of Cholinesterases and a Therapeutically
Valuable Cocaine Hydrolase for Their Catalytic Activities against Heroin and Its
Metabolite 6-monoacetylmorphine

As the most popularly abused one of opioids, heroin is actually a prodrug. In the
body, heroin is hydrolyzed/activated to 6-monoacetylmorphine (6-MAM) first and then to
morphine to produce its toxic and physiological effects. It has been known that heroin
hydrolysis to 6-MAM and morphine is accelerated by cholinesterases, including
acetylcholinesterase (AChE) and/or butyrylcholinesterase (BChE). However, there has
been controversy over the specific catalytic activities and functional significance of the
cholinesterases, which requires for the more careful kinetic characterization under the same
experimental conditions. In this study,248 the kinetic characterization of AChE, BChE, and
a therapeutically promising cocaine hydrolase (CocH1) for heroin and 6-MAM hydrolyses
under the same experimental conditions. The research described in this chapter has been
published in Chemico-Biological Interactions.249 It has been demonstrated that AChE and
BChE have similar kcat values (2100 and 1840 min-1, respectively) against heroin, but with
a large difference in KM (2170 and 120 µM, respectively). Both AChE and BChE can
catalyze 6-MAM hydrolysis to morphine, with relatively lower catalytic efficiency
compared to the heroin hydrolysis. CocH1 can also catalyze hydrolysis of heroin (kcat=2150
min-1 and KM=245 µM) and 6-MAM (kcat=0.223 min-1 and KM=292 µM), with relatively
larger KM values and lower catalytic efficiency compared to BChE. Notably, the KM values
of CocH1 against both heroin and 6-MAM are all much larger than previously reported
maximum serum heroin and 6-MAM concentrations observed in heroin users. We also
found that (–)-cocaine degradation by CocH1 was not significantly changed in the presence
of even an abnormally high concentration (100 µM) of heroin or 6-MAM. These findings
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imply that the heroin use along with cocaine will not drastically affect the catalytic activity
of CocH1 against cocaine in the CocH1-based enzyme therapy for cocaine abuse.
Dr. Jianzhuang Yao performed molecular modeling study. Dr. Zhenyu Jin helped
me to prepare cocaine hydrolases. I performed all the rest experiments described in this
chapter.

3.1 Heroin hydrolysis to morphine by human cholinesterase
Heroin (3,6-diacetylmorphine) is one of the drugs most commonly co-abused by
cocaine-dependent individuals.250-255 The concurrent use of cocaine and heroin has
received increasing clinical attentions because it not only causes more serious morbid
psychopathology256-257 and poor addiction treatment outcomes,258-259 but also considerably
increases the risk of severe drug overdose which ends in death.260
Considering the frequent use of cocaine in combination with heroin by addicts, a
question is whether or not cocaine degradation by CocH1, the first one of our discovered
high-activity mutants of human BChE, is significantly inhibited by heroin or its metabolites
6-monoacetylmorphine (6-MAM) and morphine. In fact, heroin is quickly converted to 6MAM and then more slowly to morphine in the circulating system261-263 and two human
cholinesterases, plasma BChE and erythrocyte acetylcholinesterase (AChE), are generally
regarded as the principal enzymes involved in both the majority of 6-MAM formation and
significant morphine production from heroin.
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Figure 3.1 Schematic presentation of heroin hydrolysis to morphine.

It has been demonstrated that 6-MAM is the primary metabolite responsible for
heroin’s acute psychoactive effects (the rush) and intoxication, but the euphoria following
the rush is more due to the stimulant effects of morphine produced from 6-MAM
hydrolysis,264-267 indicating the importance of the rates of 6-MAM formation and
degradation in the onset of heroin effects on the central nervous system. At heroin blood
concentrations attainable in vivo ≤ 270 nM,261, 264, 268-269 ~80% of the total heroin hydrolysis
in blood is accounted for plasma and erythrocyte cytosol where BChE and AChE are
located, respectively.270-272 In vitro enzyme kinetic studies using purified native human
cholinesterases further demonstrated that BChE, rather than AChE, is mainly responsible
for degradation of heroin to 6-MAM with a higher catalytic efficiency under first-order
kinetics.273 However, there has been controversy over the catalytic activity and functional
significance of the cholinesterases (AChE and BChE) on the hydrolysis of 6-MAM to
morphine,250,

273-274

which makes it difficult to interpret their actual roles in 6-MAM

degradation. In addition, the reported values of the kinetic parameters (kcat and KM) for
BChE against heroin ranged from 12.9 to 540 min-1 and from 0.11 to 3.5 mM,
respectively,250, 273-274 requiring for the more careful kinetic characterization under the same
experimental conditions.
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Table 3.1 The reported kinetic parameters of human BChE for heroin hydrolysis
Protein

Reference

Protein source

KM
(µM)

Lockridge et al., 1980 Human plasma
Human
BChE

Salmon et al., 1999 Human serum

110
110

k cat
-1

(min )
500
540

Kamendulis et al., 1996 Human serum 3500 ± 400 12.9 ± 0.5

Incubation condition
Temp.

pH

Heroin conc. (mM)

o

7.4

0.16 to 2

67 mM Sodium phosphate

o

7.4

0.032 to 4

100 mM Sodium phosphate

o

7.5

0 to 12

50 mM Potassium phosphat

25 C
37 C
37 C

Buffer

3.2 The focuses of this research
Here we kinetically compared CHO cell-expressed human recombinant AChE,
BChE, and CocH1 with the aims to examine their catalytic efficiencies against heroin and
6-MAM and to assess the possible interaction between cocaine and heroin or 6-MAM in
their hydrolysis reactions catalyzed by CocH1 in comparison with human enzymes AChE
and BChE. The complete catalytic parameters obtained for AChE, BChE, and CocH1
against heroin and 6-MAM reveal how the abused drugs (cocaine and heroin) can possibly
affect each other in terms of their hydrolysis reactions and detoxification under various
conditions. The insights from the kinetic characterization will be valuable in guiding
further development of novel enzyme therapies for the drug detoxification. In particular,
concurrent use of heroin and cocaine is not expected to significantly affect the efficacy of
CocH1 (or its fusion protein form TV-1380) in cocaine detoxification.
3.3 Results & Discussion
3.3.1 Identification of Fc variants with altered binding
Two previously reported studies led to contradictory findings over the ability of
BChE to catalyze hydrolysis of 6-MAM to morphine,250,

273-274

which limits the

interpretation of the data concerning the actual contributions of the enzymes to the drug
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metabolism to morphine in blood. In 1999, Salmon and his colleagues reported that only
AChE, but not BChE, further hydrolyzes 6-MAM to morphine from heroin,273 but these
findings are opposite to the previous observations of Kamendulis et al. showing the
capability of BChE to catalyze 6-MAM into morphine (kcat = 0.25 min-1 and KM = 8.6
mM).250 Therefore, we first tested whether or not heroin is metabolized to 6-MAM and
then eventually into morphine by recombinant human BChE or AChE. For each enzyme,
1 mM heroin was incubated with 4 µM enzyme. As shown in Fig. 3.2, in the presence of
either BChE or AChE, after 25 minutes of incubation, heroin has completely been
converted to 6-MAM, and some 6-MAM has further been converted to morphine. Both
BChE and AChE were highly active in metabolizing heroin to 6-MAM, but they were less
active in further degrading 6-MAM to morphine. These results clearly show that like AChE,
BChE is capable of hydrolyzing heroin to morphine eventually, which are in agreement
with the findings of Kamendulis et al.,250 but unlike the observations of Salmon et al..273
We also observed that AChE produced more morphine than BChE in the given reaction
condition, implying the relatively lower catalytic efficiency of BChE against 6-MAM.

Figure 3.2 Enzymatic activity of BChE and AChE on the hydrolysis of heroin.
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Chromatograms for the deacetylation of heroin in the presence or absence of BChE or
AChE. Peak 1 (morphine) with retention time 3.8 min, peak 2 (6-MAM) with retention
time 4.9 min and peak 3 (heroin) with retention time 14 min. The enzyme (AChE or BChE)
was incubated with 1 mM substrate concentration at 40 µM designated enzyme at 37oC for
25 min.

3.3.2 Hydrolysis of free 6-MAM to morphine by human recombinant BChE and
AChE
In a previous report by Salmon et al.,273 it was noted that AChE hydrolyzes 6-MAM
only when 6-MAM is produced from heroin within its active site and free 6-MAM
molecules only serve as an inhibitor for AChE.273 This led us to examine whether free 6MAM molecules can serve as a substrate for BChE or not. To address this question, the
enzymatic activity of the enzyme (BChE or AChE) was studied using synthetic 6-MAM
which we added to the reaction system. 1 mM 6-MAM was mixed and incubated with
either 4 µM enzyme (BChE or AChE) under the incubation condition mentioned above.
The results showed that direct incubation of 6-MAM with BChE produced the amount of
morphine which is significantly larger than that in the control (without an enzyme),
demonstrating that free 6-MAM molecules can serve as a substrate for BChE (Fig. 3.3).
Interestingly, AChE also converted synthetic 6-MAM to morphine in a significant amount
comparable to that of morphine produced from heroin by AChE (Fig. 3.2 & 3.3). Overall,
these observations clearly indicate that both free heroin and 6-MAM molecules produced
after heroin uptake in the circulatory system can be metabolized to morphine by both
cholinesterases (AChE and BChE) in blood.
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Figure 3.3 Enzymatic activity of BChE and AChE on the hydrolysis of 6-MAM.
Chromatograms for the deacetylation of 6-MAM in the presence or absence of BChE or
AChE. Peak 1 (morphine) with retention time 3.8 min and peak 2 (6-MAM) with retention
time 4.9 min. The enzyme (AChE or BChE) was incubated with 1 mM substrate
concentration at 40 µM designated enzyme at 37oC for 25 min.

3.3.3 Kinetics of heroin hydrolysis by BChE, AChE, and CocH1
As a potential anti-cocaine medication, CocH1 has a considerably improved
catalytic efficiency (kcat = 3060 min-1, KM = 3.1 µM, and kcat/KM = 9.9 × 108 min− 1 · M− 1)
compared to the wild-type BChE (kcat = 4.1 min-1, KM = 4.5 µM, and kcat/KM = 9.1 × 105
min− 1 · M− 1) against (–)-cocaine. Thus, CocH1 may be used to effectively block the drug
reward for a given dose of cocaine. Considering that CocH1 is developed from human
BChE capable of metabolizing all of (–)-cocaine, heroin and its initial host metabolite 6MAM, (–)-cocaine degradation by CocH1 can be affected by the drug-drug interaction with
heroin or 6-MAM. Specifically, if heroin or 6-MAM can also be hydrolyzed by CocH1, we
would like to know the KM or the binding affinity (Kd) of the drug (heroin or 6-MAM) with
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CocH1 in order to estimate how heroin or 6-MAM could competitively inhibit CocH1 for
its catalytic activity against (–)-cocaine. In principle, for a competitive inhibition of an
enzyme, the inhibitory constant (Ki) value is equal to the corresponding Kd value (Ki = Kd).
However, the Kd value can be different from the corresponding KM value. Nevertheless, Kd
≈ KM value under the well-known rapid equilibrium assumption275 which is usually true for
enzyme-substrate binding. Hence, we may reasonably use an experimentally measured KM
of CocH1 against heroin or 6-MAM to estimate the potential inhibitory activity of heroin
or 6-MAM against CocH1-catalyzed hydrolysis of another substrate like (–)-cocaine when
Ki ≈ KM.
In order to know whether heroin or 6-MAM can significantly inhibit CocH1catalyzed hydrolysis of (–)-cocaine, we investigated kinetics of heroin degradation to 6MAM by CocH1, BChE, and AChE. Under the experimental conditions generating the
kinetic data depicted in Fig. 3.4, we only observed the metabolite 6-MAM, and there were
no detectable levels of morphine, indicating that the enzyme activity for converting 6MAM to morphine is much lower than that for converting heroin to 6-MAM.
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Figure 3.4 Kinetic analysis of heroin hydrolysis by BChE, AChE, and CocH1. The
hydrolysis of heroin to 6-MAM by BChE (A), AChE (B), and CocH1 (C) were determined
at substrate concentrations of 0.015-1.25 mM (BChE and CocH1) or 0.015-7.5 mM
(AChE). Kinetic parameters (kcat and KM) were determined by fitting the measured reaction
rate data to the Michaelis-Menten kinetic equation using the Prism5.01 software. Each dot
is the representative of the average of triplicates and its values are expressed as the mean
± standard deviation.

The obtained kinetic data are depicted in Fig. 3.4, and the kinetic parameters
obtained are summarized in Table 3.2. As shown in Table 3.2, compared to BChE, CocH1
has a higher KM value (245 µM compared to 120 µM) and a similar kcat value (2150 min− 1
compared to 1840 min− 1). The determined KM of CocH1 against heroin is ~900-fold larger
than the previously reported blood heroin concentrations attainable in vivo (≤ 0.27 µM),261,
264, 268-269

191

and ~76-fold larger than its reported KM value against (–)-cocaine (3.1 µM).190-

Generally speaking, for a given inhibitor, when the Ki value is ~900-fold larger than the

inhibitor concentration, the inhibitor can only decrease the enzyme activity by less than
~0.1%, suggesting that the blood heroin levels usually achieved by the heroin users are not
expected to significantly change the enzymatic hydrolysis of (–)-cocaine by CocH1.
Moreover, as one can see from the kinetic data in Table 3.2, AChE has ~18-fold larger KM
value (2170 µM) compared to that of BChE, but with a similar kcat value (2100 min− 1
compared to 1840 min− 1), against heroin. These data indicate that the major difference
between wild-type AChE and BChE in the catalytic efficiency against heroin (kcat/KM =
1.53 × 107 min− 1 · M− 1 for BChE vs kcat/KM = 9.68 × 105 min− 1 · M− 1 for AChE) is mainly
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attributed to their difference in the binding affinity with heroin. Our kinetic data strongly
support the argument276 that plasma BChE is the prime enzyme responsible for the rapid
enzymatic hydrolysis of the 3´-phenolic ester of heroin in the blood.

Table 3.2 Kinetic parameters of BChE, AChE, and CocH1 against heroin
a

Relative catalytic efficiency (kcat/KM)
Enzyme

kcat
(min− 1)

KM
(µM)

kcat/KM
(min− 1 · M− 1)

RCEa

R2

BChE

1840 ± 24

120 ± 5

1.53 × 107

1

0.991

AChE

2100 ± 26

2170 ± 6

9.68 × 105

0.06

0.997

CocH1

2150 ± 31

245 ± 9

8.78 × 106

0.57

0.994

In this study, our experimental KM value of BChE against heroin (120 µM) is
consistent with the earlier KM of 110 µM reported by Lockridge et al.250, 273-274 and cited
by Salmon et al.,273 but quite different from the number of Kamendulis et al. (3.5 mM).250,
273-274

The catalytic rate constant (kcat = 1840 min− 1) determined is also substantially higher

than the wide range (from 12.9 to 540 min− 1) reported by those research groups.250, 273-274
Moreover, the kinetic parameter values of AChE determined for the hydrolysis of heroin
to 6-MAM (kcat = 2100 min− 1 and KM = 2170 µM) are higher than the values (kcat = 351
min− 1 and KM = 620 µM) reported by Salmon et al..273 It is likely that the differences in
the catalytic parameters determined for the same enzymatic reactions are largely dependent
on how enzymes are prepared if all of the kinetic assays are all in readily controlled
experimental conditions. Generally, natural protein sources, especially from human or
animal tissues, have the difficulty to meet the requirements for higher retention of
functional properties including their enzymatic activities, mainly due to the complicated
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collection, treatment, storage, and extraction processes. These processes may affect the
protein structure accompanied with a change (usually a decrease) in its binding affinity and
activity, and result in inactivation or overall diminished enzymatic activity. Whereas the
kinetic studies of Lockridge et al.,250, 273-274 Salmon et al.,273 and Kamendulis et al.250, 273274

were found on the use of natural BChE or AChE extracted from human blood samples,

all the kinetic analysis in the present study were performed using the freshly expressed and
purified BChE and AChE for comparison. In addition, another external factor affecting the
enzymatic reaction kinetics is the temperature. The kinetic studies of Salmon et al.273, and
Kamendulis et al.250, 273-274 were performed at 37oC, but that of Lockridge et al.250, 273-274
was accomplished at 25oC. In this study, the same enzymatic kinetic analysis was carried
out at 37oC and the protein samples used this study are shown to have higher binding
affinity and catalytic efficiency (reflected by the lower KM and higher kcat/KM, respectively).
These observations strongly suggest that the kinetic parameters determined in the present
study are more likely to reasonably reflect the actual enzymatic activity of human BChE
and AChE against heroin.

3.3.4 Kinetics of 6-MAM hydrolysis by BChE, AChE, and CocH1
As mentioned above, 6-MAM may also potentially inhibit CocH1-catalyzed
cocaine hydrolysis because 6-MAM can also serve as a substrate for wild-type BChE (Fig.
3.2 & 3.3). To access this possibility, we examined the kinetics of 6-MAM degradation to
morphine by CocH1 as well as wild-type BChE and AChE. The catalytic parameters kcat
and KM were determined for BChE against 6-MAM, and then were compared with those
of AChE and CocH1 (Fig. 3.5 and Table 3.3).
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Figure 3.5 Kinetic analysis of 6-MAM hydrolysis by BChE, AChE, and CocH1. The
hydrolysis of heroin to 6-MAM by BChE (A), AChE (B), and CocH1 (C) were determined
at substrate concentrations of 5-2000 µM. Kinetic parameters (kcat and KM) were
determined by fitting the generated reaction rate data to the Michaelis-Menten kinetic
equation using the Prism5.01 software. Each dot is the representative of the average of
triplicates and its values are expressed as the mean ± standard deviation.

As seen in Table 3.3, the KM value of CocH1 against 6-MAM was determined to be
292 µM which is ~94-fold-larger than the reported KM value (3.1 µM) of CocH1 against
(–)-cocaine. Given that the maximum serum concentration (Cmax) of 6-MAM in humans
has been reported to range from 5.2 to 17.5 µM after intravenous heroin administration,
277-279

the KM (292 µM) of CocH1 against 6-MAM is still ~16-56-fold larger than the Cmax

of 6-MAM achieved by heroin users. In comparison, the observed peak blood (–)-cocaine
concentrations were ~3-fold higher than the KM of CocH1 against (–)-cocaine. Overall,
these data suggest that when both 6-MAM and (–)-cocaine reach their corresponding peak
concentrations in the blood, CocH1-catalyzed (–)-cocaine hydrolysis can only be inhibited
by 6-MAM for ~0.45-1.5%. The lower the 6-MAM concentration, the less the inhibition.
The potential inhibition by 6-MAM would not be significant. Hence, CocH1 can still
efficiently degrade (–)-cocaine at the 6-MAM concentrations usually achieved by heroin
users.
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Table 3.3 Kinetic parameters of BChE, AChE, and CocH1 against 6-MAM
a

Relative catalytic efficiency (kcat/KM)
Enzyme

kcat
(min− 1)

KM
(µM)

kcat /KM
(min− 1 · M− 1)

RCEa

R2

24 ± 1.4

2.71 × 103

1

0.990

BChE

0.065 ± 0.001

AChE

7.078 ± 0.141

259 ± 18

2.73 × 104

10.1

0.990

CocH1

0.223 ± 0.005

292 ± 22

0.764 × 103

0.282

0.987

According to the kinetic data in Table 3.3, the determined kcat/KM value (2.73× 104
min− 1 · M− 1) of AChE against 6-MAM was approximately 10 times greater than that (2.71
× 103 min− 1 · M− 1) of BChE against 6-MAM. Notably, these findings are in agreement
with the findings of Kamendulis et al.250, 273-274 in that BChE catalyzes the hydrolysis of 6MAM into morphine. However, our experimental KM and kcat values are much different
from the corresponding kinetic parameters reported by Kamendulis et al..250, 273-274 Our
experimental KM of 24 µM is considerably smaller than their KM of 8.6 mM and our
determined catalytic rate constant (kcat = 0.065 min-1) is also much different from the earlier
kcat of 0.25 min-1. Accounting for all of the kinetic parameters, the catalytic efficiency
(kcat/KM = 2.71 × 103 min-1 M-1) obtained for the same enzymatic hydrolysis in the present
study is ~93-fold larger than that (kcat/KM = 2.91× 101 min-1 M-1) reported by Kamendulis
et al..250, 273-274 As mentioned above, the differences in the catalytic parameters determined
for the same enzymatic reaction seem to largely rely on how BChE is prepared for the
kinetic assay. Compared to our kinetic analysis using the freshly expressed and purified
BChE, the previous kinetic analysis by Kamendulis et al.250, 273-274 was based on the use of
natural BChE extracted from human plasma samples.
Overall, all of our experimental kinetic data strongly suggest that BChE and AChE
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play distinct roles in heroin metabolism into morphine. BChE catalyzes hydrolysis of
heroin to 6-MAM with a much higher catalytic efficiency than AChE. For the further
degradation of 6-MAM to morphine, BChE has a relatively lower catalytic efficiency than
AChE.
Further, we tested whether (–)-cocaine degradation by CocH1 will be affected by
the drug-drug interaction when heroin or 6-MAM is present in the reaction system.
According to the results obtained (Fig. 3.6), (–)-cocaine degradation by CocH1 was not
significantly changed in the presence of even an abnormally high concentration (100 µM)
of heroin or 6-MAM.
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Figure 3.6 (−)-Cocaine hydrolysis by CocH1. Both the enzyme (100 ng/ml) and (−)cocaine (100 µM) were incubated together with 100 µM opioid (heroin or 6-MAM).
Presented are the residual concentrations of cocaine versus time (○, no enzyme control; ■,
only enzyme control, without opioid; ●, enzyme plus heroin; ●, enzyme plus 6-MAM).
Cocaine concentrations were determined by using sensitive radiometric assays using
[3H](−)-cocaine. Results represent two independent experiments and the values are
expressed as mean ± standard deviations.

3.3.5 Insights from molecular modeling
The reaction pathways of cholinesterase-catalyzed hydrolyses of heroin and 6MAM were studied in our previous computational studies280-281 through first-principles
quantum mechanics and molecular mechanics-free energy (QM/MM-FE) simulations. The
optimized reactant complexes (e.g. BChE complexed with heroin and 6-MAM, and AChE
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complexed with 6-MAM) obtained from our previous QM/MM studies show a couple of
important enzyme-substrate interaction features. One is the interaction between the acetyl
groups of heroin and 6-MAM and the oxyanion hole consisting of Gly116, Gly117, and
Ala199 in BChE (corresponding to Gly121, Gly122, and Ala204 in AChE). The other is
the interaction between the positively charged amino-groups of heroin and 6-MAM and
the sidechain of Trp82 in BChE (corresponding to Trp86 in AChE). Guided by the
aforementioned interactions, the substrate (heroin or 6-MAM) was docked into the active
site of the enzyme (AChE, BChE, or CocH1). The molecular docking enabled us to
understand how heroin may bind with human AChE, BChE, and CocH11 compared to 6MAM binding with the corresponding enzymes. According to the enzyme-substrate
binding structures obtained from molecular docking (as shown in Fig. 3.7), the binding
mode for each enzyme (AChE, BChE, and CocH1) with heroin is similar to that with 6MAM in terms of the overall hydrogen bonding with the oxyanion hole, particularly for
the crucial interactions between the carbonyl oxygen of the substrate and the oxyanion hole
of the enzyme. In particular, there are always two hydrogen bonds between the carbonyl
oxygen of the substrate and backbone amide groups of the oxyanion hole residues (Gly120
and Gly121 of AChE corresponding to Gly116 and Gly117 of BChE and CocH11) no
matter whether the substrate is heroin or 6-MAM. There are also two hydrogen bonds
between the carbonyl oxygen of the substrate and the oxyanion hole of CocH1 (sidechain
of Ser199 and backbone of Gly117), no matter whether the substrate is heroin or 6-MAM.
The modelling results depicted in Fig. 3.7 reveal that, no matter whether the enzyme is
AChE, BChE, or CocH1, the acetyl-group of heroin forms stronger hydrogen bonds in the
oxyanion hole compared to 6-MAM with the same enzyme. Hence, all of the enzymes
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concerned in the present study are expected to have a significantly better catalytic
efficiency against heroin compared to 6-MAM. In particular, although a novel hydrogen
bond from Ser199 of CocH1 is introduced to stabilize the acetyl-group of the substrate
(heroin or 6-MAM), the hydrogen bond with Gly116 is lost compared to wild-type BChE.
Therefore, CocH1 concerned in the present study is not expected to have a significantly
improved catalytic efficiency against heroin or 6-MAM in comparison with BChE. The
computational insight is supported by the measured kinetic parameters discussed above.
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Figure 3.7 Modeled structures of the AChE, BChE, and CocH1 (E14-3) binding with
heroin and 6-MAM. (A) Wild-type AChE binding with heroin; (B) Wild-type BChE
binding with heroin; (C) CocH1 binding with heroin; (D) Wild-type AChE binding with 6MAM; (E) Wild-type BChE binding with 6-MAM; (F) CocH1 binding with 6-MAM. This
figure was provided by Dr. Jianzhuang Yao in our lab.
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3.3.6 Main outcomes of this research
The catalytic activities of wild-type AChE, wild-type BChE, and CocH1 against
heroin and 6-MAM have been characterized under the same experimental conditions for
comparison. According to the determined kinetic parameters kcat and KM for all of these
enzymatic reactions, wild-type AChE and BChE have similar kcat values (kcat = 2100 min-1
for AChE and kcat = 1840 min-1 for BChE) against heroin. However, BChE has a ~16 foldhigher catalytic efficiency than AChE (kcat/KM = 1.53 × 107 min− 1 · M− 1 for BChE vs
kcat/KM = 9.67 × 105 min− 1 · M− 1 for AChE), mainly because BChE has a ~18-fold stronger
binding affinity with heroin compared to AChE (Kd ≈ KM = 120 µM for BChE vs Kd ≈ KM
= 2170 µM for AChE). Besides, both AChE and BChE can catalyze 6-MAM hydrolysis to
morphine, with relatively lower catalytic efficiency compared to the corresponding enzyme
catalyzing heroin hydrolysis.
CocH1 can also catalyze hydrolysis of heroin (kcat = 2150 min-1 and KM = 245 µM)
and 6-MAM (kcat = 0.223 min-1 and KM = 292 µM), with relatively larger KM values and
relatively lower catalytic efficiency compared to wild-type BChE. Notably, the KM values
of CocH1 against both heroin and 6-MAM are all much larger than previously reported
maximum serum heroin and 6-MAM concentrations observed in heroin users, implying
that the heroin use along with cocaine use will not significantly affect the catalytic activity
of CocH1 against cocaine in the CocH1-based enzyme therapy for cocaine abuse.
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3.4 Experimental details
3.4.1 Materials
Phusion DNA polymerases, restriction enzymes, and T4 DNA ligase were
purchased from New England Biolabs. All oligonucleotides were purchased from Eurofins
MWG Operon. Vector pCMV–MCS was obtained from Agilent Technologies. Chinese
hamster ovary (CHO)–S cells and FreeStyleTM CHO Expression Medium,
hypoxanthine/thymidine (HT) supplement, l-glutamine, 4–12% Tris-glycine Mini Protein
Gel, and SimpleBlue SafeStain were purchased from Life Technologies (Carlsbad, CA).
Reduction-modified protein (rmp) Protein A Sepharose Fast Flow was ordered from GE
Healthcare Life Sciences (Pittsburgh, PA). Centrifugal filter units were ordered from
Millipore (Burlington, MA). Heroin, 6-MAM, and morphine were provided by the National
Institute on Drug Abuse (NIDA) Drug Supply Program. All other chemicals as well as the
solvents used in high-performance liquid chromatography (HPLC), were of HPLC grade
and purchased from Sigma-Aldrich (St. Louis, MO).

3.4.2 Construction of mammalian expression plasmids
CocH1 truncated after amino acid 529 was fused with human serum albumin (HSA)
for the extension of biological half-life.282 For protein expression in mammalian cells, the
cDNA for the CocH1 (the A199S/F227A/S287G/A328W mutant of human BChE)
containing C-terminal HSA was generated and cloned in to pCMV-MCS in our previous
studies.190-191, 283 Two expression plasmids, pCMV-BChE-Fc(WT), and pCMV-AChEFc(WT), were constructed as described previously.87 Briefly, the C-terminal of truncated
human enzyme (BChE or AChE) was genetically fused to the N-terminal of the Fc portion
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of wild-type human IgG (Fc(WT)) by overlapping extension PCR with Phusion DNA
polymerase. Then, the PCR products were digested with restriction endonucleases Hind III
and Bgl II. The gel purified PCR products were then ligated to the pCMV-MCS expression
vector using T4 DNA ligase.

3.4.3 Protein Expression and Purification
CHO-S cells were incubated in FreeStyle CHO Expression Medium (Life
Technologies) with 8 mM l-glutamine (Life Technologies) at 37°C in a humidified
atmosphere with 8% CO2 and transfected with gene expression DNA constructs encoding
the protein of interest using the TransIT-PRO Transfection Kit (Mirus Bio LLC, Madison,
WI)) when the number of the cells reached 1.0 × 106 cells/mL. The culture medium was
harvested 6 days after transfection. The Fc-fused protein (BChE or AChE) secreted into
the culture medium was purified by protein A affinity chromatography. After removing
cells by centrifugation, the cell-free culture medium was mixed with rmp Protein A
Sepharose Fast Flow (GE Healthcare Life Sciences) pre-equilibrated with 20 mM Tris⋅HCl,
pH 7.4, and incubated for overnight at 6°C with occasional stirring. Then, the suspension
was packed in a column and washed with 5 column volume (CV) of 20 mM Tris⋅HCl, pH
7.4, containing 200 mM NaCl until an OD280 < 0.02 was achieved; then the protein was
eluted by adjustment of the pH and salt concentration. HSA-fused CocH1 was also
expressed as described above. Using the AlbuPure matrix (Prometic Life Sciences Inc.,
Laval, Canada), CocH1-HSA was purified where the cell-free culture medium was loaded
onto packed bed pre-equilibrated with 50 mM sodium acetate, pH 5.3, extensively washed
with 8 CV of equilibration buffer. Then, the resin bound protein was eluted with 5 CV of
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50 mM ammonium acetate, pH 7.4. For buffer exchange, the eluate was dialyzed in storage
buffer (50 mM Hepes, 20% sorbitol, 1 M glycine, pH 7.4) by Millipore Centrifugal Filter
Units. The entire purification process was performed in a cold room at 8°C and the purified
proteins were stored at −80°C until the activity tests.

3.4.4 Enzyme Activity Assays
Enzymatic hydrolyses of heroin to 6-MAM and 6-MAM to morphine were tested
under the following assay conditions. Incubations (50 µl final volume) contained purified
enzyme and heroin or 6-monoacetylmorphine (6-MAM) in 0.1 M phosphate buffer, pH 7.4.
All the activity assays were performed at 37°C. For heroin hydrolysis, 0.02 to 2.5 mM
heroin was incubated with 35 nM designated enzyme. For 6-MAM hydrolysis, 0.002 to 2
mM 6-MAM was incubated with 2 µM designated enzyme. The reaction time and
concentration were adjusted such that no more than 10% of substrate was depleted during
reaction. The reaction was terminated, and protein was precipitated by the addition of 100
µl of iced 50% acetonitrile/0.5 M hydrochloric acid, followed by 5 min centrifugation at
15,000 g. The resulting supernatants were subjected to reverse-phase HPLC (RP-HPLC)
on a 5 µm C18 110 Å column (250 × 4.6 mm; Gemini) (Life Technologies) and RP-HPLC
was performed using the mobile phase consisting of 20% acetonitrile in 0.1% TFA. The
remaining substrate and resulting products were monitored by a fluorescence detector with
an excitation wavelength of 230 nm and emission wavelength of 315 nm and by monitoring
UV absorbance at 230 nm. The quantification was based on a standard curve prepared using
an authentic standard compound.
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3.4.5 Molecular modelling
Heroin and 6-MAM binding with human AChE, BChE, and CocH1 were modelled
by using our previously modelled structures of the same enzymes.280-281, 284-285 Our previous
molecular dynamics (MD) simulations on the structures of enzyme-substrate complexes
started from the X-Ray crystal structures deposited in the protein databank (PDB) (AChE:
code 1B41; BChE: 2XQF and 1P0P). Molecular docking and subsequent optimization were
carried out using a similar protocol described previously.280 Briefly, the acetyl group of the
substrate (heroin or 6-MAM) was positioned in the oxyanion hole (consisting of Gly116,
Gly117, and Ala199 in BChE, or Gly121, Gly122, and Ala204 in AChE, or Gly116, Gly117,
and Ser199 in CocH1), and the positively charged amino-group of the substrate (heroin and
6-MAM) was placed in the choline-binding site near Trp82 in BChE and CocH1 or Trp86
in AChE. Finally, the binding models of heroin and 6-MAM in the corresponding enzymesubstrate complexes were optimized by performing the energy minimization.
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Chapter Ⅳ. Oligomerization and Catalytic Parameters of Human UDPglucuronosyltransferase 1A10

Uridine

5'-diphospho-glucuronosyltransferase (UDP-glucuronosyltransferase,

UGT), as an integral membrane protein localized in the endoplasmic reticulum, has the
ability to detoxify potentially hazardous xenobiotic substances. Most UGTs are expressed
in liver, but UGT1A10 has proven an extra-hepatic enzyme considerably expressed
throughout the gastrointestinal track. Earlier studies indicated that different UGT isoforms
could exist in higher-order homo-oligomers or at least dimers within the membrane, but
the formation of intermolecular disulfide bridges between UGT molecules was not often
observed. In this study,286 we expressed recombinant human UGT1A10 in HEK293 and
CHO cells to examine its oligomeric states and characterize its enzymatic activities against
two therapeutically interesting substrates, morphine and entacapone, including
determination of the catalytic rate constant (kcat) values for the first time. The research
described in this chapter has been published in to Drug Metabolism and Distribution.287 It
was observed that majority of the UGT1A10 protein expressed in HEK293 cells existed in
covalently cross-linked higher-order oligomers via formation of intermolecular disulfide
bonds, whereas formation of the intermolecular disulfide bonds was not observed in the
UGT1A10 protein expressed in CHO cells. Due to the formation of the covalently crosslinked higher-order oligomers, the UGT1A10 protein expressed in HEK293 cells had much
lower catalytic activities (particularly the catalytic rate constant kcat) against both morphine
and entacapone, compared to the UGT1A10 protein form expressed in CHO cells against
the corresponding substrates.
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4.1 UDP-glucuronosyltransferase (UGT)
UGTs are membrane-bound proteins localized in the endoplasmic reticulum (ER).
These proteins catalyze the glucuronic acid transfer from UDP-glucuronic acids (UDP-GA)
to small molecules (substrates). Human UGTs are divided into two gene families, UGT1
and UGT2, based on evolutionary divergence288 and play a crucial role in detoxification
and excretion of potentially hazardous xenobiotics as well as endogenous substances.
However, it has been difficult to study the catalytic activity of an individual UGT in native
tissues because many different UGTs are expressed in the same tissues such as liver and
their substrate specificities have proven overlapped frequently. Therefore, it has become
common in the field to use recombinant enzymes exogenously expressed in different cell
lines, when testing whether a specific substrate of interest is converted by a UGT isomer
into a glucuronide form and comparing the catalytic efficiencies of UGT isoforms against
a specific substrate. Added to this, the absence of a suitable method to purify UGTs as
sufficiently active and mono-dispersed proteins has limited the studies toward
understanding the structure-function relationships of these proteins.
Morphine remains the most valuable opioid analgesic for the management of
moderate to severe pain.289 Morphine undergoes a considerable first-pass metabolism by
UGTs in animals and humans after oral administration. The inactive morphine-3glucuronide (M3G) and analgesically potent morphine-6-glucuronide (M6G) are the major
metabolites of morphine in the body and they are mainly excreted by the urinary system.290292

Although human liver still appears to be a prime organ responsible for the formation of

morphine glucuronides,290 the respective contribution of the gastrointestinal tract and liver
to the first-pass extraction of orally administrated morphine remains unclear.292 In 2003, a
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systemic study of the recombinant human UGT isoforms related to morphine
glucuronidation showed that UGT1A10, an extra-hepatic enzyme restrictively expressed
in the digestive tract, catalyzes the conversion of morphine to M3G, not M6G, with a
relatively higher rate, compared to the other UGT1A isoforms tested (UGT1A1, 1A3, 1A6,
1A8, and 1A9).293 However, their report only compared the measured Vmax and KM values
of UGT isomers for the M3G formation, and they were unable to determine their actual
catalytic rate constant (kcat) values, which limits the interpretation of the kinetic data
concerning the actual catalytic activities of individual UGTs.

Table 4.1 Kinetic constants for morphine 3- and 6-glucuronide formation by human
recombinant UDP-glucuronosyltransferases stably expressed in HEK293 cells.293

Human UGTs

Vmax
(pmol/min/mg)

KM
(mM)

UGT1A10

628.2 ± 92.4

12.6 ± 2.6

UGT2B7

183.3 ± 15.4

58.3 ± 3.2

UGT1A9

31.7 ± 3.1

37.4 ± 5.6

UGT1A6

20.8 ± 2.6

18.0 ± 3.7

UGT1A8

12.9 ± 1.0

2.6 ± 0.3

UGT1A3

10.3 ± 0.6

3.2 ± 0.3

UGT1A1

4.5 ± 0.2

18.7 ± 1.4

71

4.2 The focuses of this research
In the present study, we first analyzed the expression of recombinant human
UGT1A10 protein in HEK293 and CHO cells by western blotting. Then, we kinetically
characterized its glucuronidating activities for two different substrates, morphine and
entacapone, an inhibitor of catechol-O-methyltransferase (COMT) used in the treatment of
Parkinson’s disease. The kinetic characterization has allowed us to determine the kcat values
of UGT1A10 against morphine and entacapone for the first time. It has also been
demonstrated that recombinant human UGT1A10 protein expressed in HEK293 cells
forms oligomerized complexes that are covalently cross-linked by disulfide bonds, but that
expressed in CHO cells barely forms cross-linked disulfide bonds. In addition, the
complete catalytic parameters obtained for membrane-bound UGT1A10 against morphine
and entacapone reveal that the catalytic activities of recombinant UGT1A10 proteins are
remarkably different, depending on which type of cell line is used to express the protein.

4.3 Results
4.3.1 Overexpression of human UGT1A10 in CHO and HEK293 cells
When expressed in CHO and HEK293 cells, recombinant human UGT1A10
protein was detected majorly at ~65 kDa (monomeric size) by immunoblotting with an
anti-UGT1A antiserum. After longer exposure UGT1A10 protein was also observed as
unexpected bands at approximately ~130 kDa, and higher than ~130 kDa in both
microsomes prepared from UGT1A10-6xHis-overexpressing stable CHO or HEK293 cells
(three independent western blotting tests showed the same bands) (Fig. 4.1). The bands
with molecular weight higher than ~65 kDa are neither endogenous UGT1A nor UGT2B
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isoforms as they were not detected in the microsomal proteins of native CHO and HEK293
cells by immunoblotting with anti-UGT1A or UGT1B antiserum (data not shown), which
indicates that the unexpected high molecular-weight bands were extremely stable homooligomers of UGT1A10 or hetero-oligomeric complexes with another protein.

Figure 4.1 Western blot analysis of UGT1A10 protein in microsomes prepared from
UGT1A10-6xHis-overexpressing stable CHO and HEK293 cell lines. Microsomes were
boiled at 95oC for 10 min in the presence of 100 mM dithiothreitol (DTT) prior to
electrophoresis

Previously, Matern et al.294 showed that a form of active rat UGT extracted from
rat liver appears with an apparent molecular mass = 316 kDa and the subunit molecular
weight was determined as ~54 kDa, suggesting that the formation of oligomeric UGT
complexes occurred naturally or inadvertently after purification. In line with this, recent
reports also support295-297 that the UGT proteins existed in the membrane tissue as higherorder oligomers (at least dimers). These observations led us to test whether the majority of
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recombinant human UGT1A10 enzyme in CHO and HEK293 cells are also highly
organized within the membrane of ER and exist as homo-oligomeric complexes. For this
purpose, UGT1A10 proteins in microsomes prepared from the stable cell lines indicated
above were first exposed to different denaturating conditions then separated on SDS-PAGE
followed by immunoblot detection with anti-UGT1A antibody as described in the material
method section. We found that the majority of HEK293-expressed UGT1A10
(UGT1A10HEK293) enzyme molecules formed the higher-order oligomers that were
completely resolved to the monomeric size of UGT1A10 upon SDS-PAGE after treatment
with dithiothreitol (DTT) and the minority migrate as a dimer after reduction. However,
the covalently cross-linked higher-order oligomers were not observed in the CHOexpressed UGT1A10 (UGT1A10CHO). Boiling the samples neither formed aggregates of
UGT1A10 proteins nor made changes in the results (Fig. 4.2). To examine whether the
oligomeric UGT1A10 complexes seen in the stable HEK293 cells are homeric or
heteromeric, anti-UGT1A immunoprecipitation was performed. However, whereas
UGT1A10CHO enzyme was efficiently precipitated, UGT1A10HEK293 enzyme was not in the
same experimental condition.
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Figure 4.2 Analysis of recombinant UGT1A10 expression. SDS-polyacrylamide gel
electrophoresis of microsomes under different denaturating conditions, followed by
immunoblot analysis. DTT, electrophoresis after reduction with 100 mM DTT; Boiling,
electrophoresis after boiling; No treatment, No DTT and boiling before electrophoresis.

4.3.2 Quantification of the levels of recombinant UGT1A10 in microsomes prepared
from stable cells
Considering that disulfide bridges considerably contribute to the interaction of
UGT1A10 expressed in HEK293, but not in CHO cells, a question was whether the
UGT1A10 enzyme activity may be altered by the formation of intermolecular crosslinks
via disulfide bonds between UGT1A10 molecules. To address the question, the
concentrations of UGT1A10 expressed using the two stable cell lines were first determined
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and then their kinetic parameters (kcat and KM) values were evaluated and compared in
subsequent kinetic assays. As shown in Fig. 4.3A, we purified UGT1A10 from microsome
prepared from the UGT1A10-6xHis-overexpressing stable CHO cells and determined its
concentration as noted in the Materials and Method section. Differing amounts of purified
UGT1A10 were then loaded as indicated to obtain a single blot with densitometric readings
on the linear part of the curve for membrane-bound UGT1A10 in microsomes (Fig 4.3B &
C). The concentrations of membrane-bound UGT1A10 in microsomes prepared from the
stable HEK293 and CHO cells were determined to be 6.69 and 3.02 ng/μg of microsomal
proteins, respectively.

76

Figure 4.3 Quantification of the levels of UGT1A10 in microsomes. (A) SDS-PAGE
analysis of pure UGT1A10-6xHis extracted from microsome prepared from UGT1A106xHis-overexpressing stale CHO cells. The sizes of the molecular mass markers are
indicated on the left in kDa. (B) Chemiluminescent blot of dilution series of purified
UGT1A10-6xHis and two unknown amounts of membrane-bound UGT1A10-6xHis. (C)
The linear dynamic range of film-based detection for UGT1A10-6xHis. The graph shows
a quantitative level of UGT1A10-6xHis protein for the corresponding chemiluminescence
signal intensity. Each dot represents the average of duplicates and its values are expressed
as the mean ± standard deviation.
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4.3.3 Kinetics of morphine glucuronidation by recombinant human UGT1A10
To test whether HEK293- and CHO-expressed UGT1A10 proteins forms have a
similar catalytic activity against morphine, we investigated the kinetics for the formation
of morphine-3-glucuronide (M3G) catalyzed by UGT1A10. As shown in a representative
of HPLC chromatograms depicting the peak for M3G (Fig. 4.4A), the glucuronidation
activity was observed for both membrane-bound UGT1A10CHO or UGT1A10HEK293
enzymes against morphine (Fig. 4.4, top and middle) and the peak (M3G) with a retention
time of 5.4 min disappeared after β-glucuronidase was added to the reaction (Fig. 4.4,
bottom).

78

Figure 4.4 Kinetic analysis of the formation of morphine-3-glucuronide (M3G) by
UGT1A10. (A) High-performance liquid chromatography (HPLC) analysis of M3G
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formation using microsomes prepared from UGT1A10-6xHis-overexpressing stable cell
lines. Top, membrane-bound UGT1A10-6xHis expressed in CHO cells; middle,
membrane-bound UGT1A10-6xHis expressed in HEK293 cells; bottom, membrane-bound
UGT1A10-6xHis expressed in HEK293 cells with treatment with β-glucuronidase. (B)
M3G formation by membrane-bound UGT1A10-6xHis enzymes in CHO cells (●) or in
HEK293 cells (○), or by purified UGT1A10-6xHis protein (■) were determined at substrate
concentrations of 0.1 to 20 mM. Kinetic parameters (kcat and KM) were determined by
fitting the measured reaction rate data to the Michaelis-Menten kinetic equation using the
Prism5.01 software. Each dot is the representative of the average of triplicates and its
values are expressed as the mean ± standard deviation.

The generated kinetic data are depicted in Fig. 4.4B, and the kinetic parameters
obtained are summarized in Table 4.2. As shown in Table 4.2, compared to membranebound UGT1A10HEK293, membrane-bound UGT1A10CHO had a higher kcat value (8.26 min−
1

compared to 0.90 min− 1) and a slightly lower KM value (7.3 mM compared to 10.4 mM).

These data indicate that the major difference between membrane-bound UGT1A10CHO and
UGT1A10HEK293 in the catalytic efficiency against morphine (kcat/KM = 1.13 × 103 min−
1

· M− 1 for UGT1A10CHO vs kcat/KM = 86.51min− 1 · M− 1 for UGT1A10HEK293) is largely

attributed to their turnover numbers (kcat) for the M3G formation. However,
glucuronidation of morphine by the purified UGT1A10 was not observed under the
experimental conditions generating the kinetic data depicted in Fig. 4.4B.
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Table 4.2 Kinetic parameters of human UGT1A10-6xHis against morphine
a

Relative catalytic efficiency (kcat/KM)
UGT1A10-6xHis

RCEa

R2

86.51

1

0.994

1.13 × 103

13.0

0.988

KM

kcat

kcat/KM

mM

min − 1

min − 1 · M − 1

Membrane-bound_HEK293

10.4 ± 0.96

0.90 ± 0.04

Membrane-bound_CHO

7.30 ± 0.81

8.26 ± 0.38

4.3.4 Kinetics of entacapone glucuronidation by recombinant human UGT1A10
Entacapone is an inhibitor of catechol-O-methyltransferase (COMT) used in the
treatment of Parkinson’s disease. Entacapone is known to be metabolized into entacapone
3-O-glucuronide by different UGTs. As shown in Fig. 4.5, the peak for entacapone 3-Oglucuronide (retention time = 9.9 min) appeared in the presence of membrane-bound
UGT1A10CHO or UGT1A10HEK293 (top and middle) enzyme, and the peak was no longer
found if the reaction was further incubated with β-glucuronidase (bottom), indicating that
entacapone was recognized by both the membrane-bound UGT1A10 enzyme forms as a
substrate.
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Figure 4.5 HPLC analysis of the formation of entacapone 3-O-glucuronide using
microsomes prepared from UGT1A10-6xHis-overexpressing stable cell lines. Top,
membrane-bound UGT1A10-6xHis expressed in CHO cells; middle, membrane-bound
UGT1A10-6xHis expressed in HEK293 cells; bottom, membrane-bound UGT1A10-6xHis
expressed in HEK293 cells with treatment with β-glucuronidase.
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To assess whether the observed differences in the catalytic activity against
morphine between membrane-bound UGT1A10CHO and UGT1A10HEK293 are also
manifested against a different substrate, additional kinetic assay was performed against
entacapone. The obtained kinetic data are depicted in Fig. 4.6A, and the kinetic parameters
determined are summarized in Table 4.3.

Figure 4.6 Kinetic analysis of entacapone 3-O-glucuronide formation by UGT1A10. (A)
Formation of entacapone 3-O-glucuronide by membrane-bound UGT1A10-6xHis protein
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in CHO cells (●), or in HEK293 cells (○) were determined at substrate concentrations of 3
to 2000 μM. (B) Formation of entacapone 3-O-glucuronide by purified UGT1A10-6xHis
protein was determined at substrate concentrations of 3 to 2000 μM in the presence (●) or
absence (○) of 1 mg/ml of phosphatidylcholine type X-E. Kinetic parameters (kcat and KM)
were determined by fitting the generated reaction rate data to the Michaelis-Menten kinetic
equation using the Prism5.01 software. Each dot refers to the average of duplicate or
triplicates and its values are expressed as the mean ± standard deviation.

As shown in Table 4.3, the expected similar differences in glucuronidation kinetics
for entacapone were also observed between membrane-bound UGT1A10CHO and
UGT1A10HEK293. A substantially higher catalytic efficiency against entacapone was
observed for membrane-bound UGT1A10CHO compared to UGT1A10HEK293 (5.53 × 105
min− 1 · M− 1 compared to 7.71 × 104 min− 1 · M− 1) and this difference is mainly due to a
substantially higher kcat value (25.3 min− 1 compared to 4.39 min− 1) and a slightly lower
KM value (45.7 µM compared to 56.9 µM) of membrane-bound UGT1A10CHO compared
to membrane-bound UGT1A10HEK293.
Added to this, although the purified UGT1A10 showed a detectable enzymatic
activity toward entacapone, the experimental KM and kcat values of membrane
UGT1A10CHO were indeed increased by a factor of about 15 (45.7 µM compared to 703
µM) and decreased by a factor of about 320 (25.3 min− 1 compared to 0.079 min− 1),
respectively, during the purification process (Table 4.3). Moreover, it was observed that the
rate constant of entacapone glucuronidation by the purified UGT1A10 was only slightly
increased by the addition of phospholipid sonicated (Fig. 4.6B & Table 4.3).
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Table 4.3 Kinetic parameters of human UGT1A10-6xHis against entacapone
a

Relative catalytic efficiency (kcat/KM)
UGT1A10-6xHis

Membrane-bound_HEK293
Membrane-bound_CHO

KM

kcat

kcat/KM

µM

min − 1

min − 1 · M − 1

56.9 ± 4.1

4.39 ± 0.07

7.71 × 104

45.7 ± 4.5

25.3 ± 0.6

5.53 × 10

5

RCEa

R2

1

0.987

7.17

0.992

Purified_CHO w/o phospholipid

703 ± 116 0.079 ± 0.005

1.12 × 102

1.45 × 10-3 0.991

Purified_CHO w/ phospholipid

554 ± 72

2.88 × 102

3.74 × 10-3 0.995

0.16 ± 0.01

4.4 Discussion and Conclusion
An extrahepatic human UGT1A10 was expressed as an active enzyme using
lentivirus-infected HEK293 and CHO cells. Our recombinant UGT1A10 has a C-terminal
hexa-histidine tag which allows for efficient single-step chromatographic purification
using IMAC. Indeed, human recombinant UGTs containing a His tag at the C-terminus
have been widely used for the enzymatic characterization, structure determination, and
substrate screening studies of the UGTs.137, 298-301 Zhang et al.302 demonstrated that only
mild increase in the KM values was observed in UGT1A9 and 2B7 containing the Cterminal His-tag, but no differences in parameters such as the kinetic model. In consistent
with the findings, we also found that CHO-expressed recombinant UGT1A10 proteins
displayed a similar KM values for morphine (KM = 7.30 ± 0.81 mM for UGT1A10-6xHis
vs KM = 6.60 ± 0.33 mM for UGT1A10), regardless of whether or not it had the addition
of a His tag to its C-terminal end, which suggests that UGT1A10-6xHis is a good model
for the functional studies.
Previously, Kurkela et al.298 reported a good method to purify human UGT1A9 as
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an active form using Triton X-100. In this study, we demonstrated that their method also
works for purification of active UGT1A10 which shares about 93.2% identical protein
sequence with UGT1A9. However, the purification process caused an irreversible and
considerable decrease in UGT1A10 enzymatic activity, which cannot be merely
compensated by phospholipid addition. Actually, this observation is consistent with the
findings of Kurkela et al..298 Compared to membrane-bound UGT1A10CHO, the KM and kcat
values for entacapone were reduced ~15 and ~320 times, respectively, during the
purification process.
The oligomeric states of the UGTs have been studied for more than two decades.
One of the main reasons for the attempts was to answer the question concerning whether
or not the enzymatic activities of the UGTs are affected by their oligomeric states. The two
previous studies studying pure UGT isoforms extracted from the native tissues showed that
UGTs could be present as tetramers or even higher-order oligomers.294, 303 By nearestneighbor cross-linking and yeast two-hybrid analysis, Ghosh et al.295 also revealed that
recombinant human UGT1A1 enzymes within microsomal membrane form homooligomers. Added to this, a study using fluorescence resonance energy transfer as a tool to
demonstrate oligomerization of UGT1A7 proteins reported296 that ~90% of UGT1A7
proteins existed as homo-oligomeric complexes in live cells. In this study, we found that
most of recombinant human UGT1A10 enzymes expressed in HEK293 cells formed the
covalently cross-linked higher-order oligomers via intermolecular disulfide bonds (Fig.
4.2). To the best of our knowledge, this is not only the first demonstration of the
oligomerized UGT1A10 complexes, but also the first evidence to show the presence of
complicated disulfide bridges to form higher-order UGT complexes bigger than a dimer.
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Considering that the covalently cross-linked homo-oligomers are not frequently observed
in recombinant human UGT1A1, 1A4, and 1A6 enzymes expressed in HEK293 cells, as
reported by Fujiwara et al.,304 the observed multiple disulfide bonds formed in the
oligomerized UGT1A10 complexes seem to be unique.
Interestingly, we also found that CHO-expressed UGT1A10 was barely crosslinked via disulfide bridges, unlike the HEK293-expressed UGT1A10 (Fig. 4.1 & 4,2).
This finding led us to ask whether there is any difference in activity between these
UGT1A10 enzyme forms. Our kinetic assays on the HEK- and CHO-expressed UGT1A10
enzyme forms for their catalytic activities against morphine and entacapone revealed that
HEK293-expressed UGT1A10 had a similar KM value, but a substantially decreased kcat
value, compared to the CHO-expressed UGT1A10. These findings suggest that the
intermolecular disulfide bonds in the HEK293-expressed UGT1A10 protein would
substantially decrease the catalytic activities of the enzyme against both of the substrates
(Tables 4.2 & 4.3). However, since the UGT1A10 enzyme forms in the microsomal
fractions, not the purified enzyme forms, were utilized for our enzyme activity assays, we
still cannot completely rule out alternative possibilities such as the presence of another key
determinant of UGT1A10 enzyme activity. Indeed, we also tested whether an enzymatic
activity of HEK293-expressed UGT1A10 can increase by disrupting the S-S bonds. It was
observed that both membrane-bound UGT1A10HEK293 and UGT1A10CHO became inactive
after incubated with 100 mM DTT for 1 hr, which strongly suggests that the intramolecular
disulfide bonds of UGT1A10 enzyme are crucial for its activity or stability. Despite of the
experimental limitation, our observations clearly indicate that the enzymatic activity and
post-translational modification of UGT1A10 can be significantly affected by the cell line
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used to express the protein. In addition, according to the modeled van der Waals surface of
the UGT1A10 protein structure (Fig. 4.7),287 UGT1A10 has three cysteine residues (C72,
C183, and C277) on the protein surface. C183 of one UGT1A10 molecule could form a
disulfide bond with C72 or C277 of another UGT1A10 molecule, i.e. forming
intermolecular disulfide bonds. Further, there are multiple asparagine residues (that are
potential glycosylation sites) nearby C72 and C277 on the protein surface. Different glycan
structures formed in different types of cells could have differential effects on formation of
the intermolecular disulfide crosslinks, which helps us to understand the observed
remarkable oligomerization difference between the two cell lines.

Figure 4.7 The modeled van der Waals surface of the UGT1A10 protein structure, showing
three solvent-accessible cysteine residues (C72, C183, and C277 in green color). Panels A
and B show two sides of the protein, with C72 and C277 on one side and C183 on the
opposite side. Indicated in red color are solvent-accessible asparagine residues (potential
glycosylation sites). C72 and C277 are close to the entrance of the enzyme active-site
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pocket. C72 or C277 of a UGT1A10 molecule may form a disulfide bond with C183 or
C72 or C277 of another UGT1A10 molecule for crosslinking via intermolecular disulfide
bonds. The crosslinking disulfide bonds involving C72 or C277 are expected to block the
entrance of the enzyme active-site pocket and, thus, decrease the catalytic activity of the
enzyme. The figure was provided by Drs. Kuo-Hao Lee and Yaxia Yuan.

Considering that a non-hepatic UGT1A10 enzyme is substantially expressed in
human small intestine and colon with UGT1A1, 2B7, 2B15, and 2B17,305-308 there still
remains notable interest in the potential contributions of these enzymes to the first-pass
metabolism of morphine in the gastrointestinal track after oral uptake. This is the first
report of the complete kinetic parameters (kcat and KM) of UGT1A10 against morphine and
entacapone. Extending the lines of this study using the UGTs mentioned above will help to
enhance our understanding of their significant contributions to the first-pass extraction of
orally administered drugs including morphine.
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4.5 Experimental details
4.5.1 Chemicals and Materials
Phusion DNA polymerases, restriction enzymes, and T4 DNA ligase were
purchased from New England Biolabs (Ipswich, MA). All oligonucleotides were purchased
from Eurofins MWG Operon (Louisville, KY). Chinese hamster ovary (CHO)–S cells, 293
human embryonic kidney–F (HEK293) cells, HEK-293FT, FreeStyleTM CHO Expression
Medium, FreeStyle™ 293 Expression Medium, hypoxanthine/thymidine (HT) supplement,
l-glutamine, 4–12% Tris-glycine Mini Protein Gel, and SimpleBlue SafeStain were
purchased from Life Technologies (Carlsbad, CA). Morphine was provided by the National
Institute on Drug Abuse (NIDA) Drug Supply Program. Morphine-3-glucuronide,
entacapone, entacapone 3-O-glucuronide, UDP-GA, Triton X-100, saccharolactone, βglucuronidase, phospholipids (phosphatidylcholine type X-E) and the solvents used in
high-performance liquid chromatography (HPLC) were purchased from Sigma-Aldrich (St.
Louis, MO). HisPur™ Cobalt Resin was obtained from Thermo Fisher Scientific (Waltham,
MA). Centrifugal filter units were ordered from Millipore (Burlington, MA).

4.5.2 Generation of the stable cell line by lentivirus infection
Cell lines stably overexpressing human UGT1A10 were generated using a
lentivirus-based method described in our previous report.309 The human UGT1A10-6xHis
gene was first synthesized by Genscript Corporation (Piscataway, NJ) based on the
published sequence in GenBank (NM_019075.2) and inserted in the pCSC-SP-PW vector,
lentivirus plasmid. In order to package the lentivirus particles carrying UGT1A10-6xHis
gene, lentivirus was produced by co-transfecting pCSC-human UGT1A10-6xHis plasmid
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with the two packaging vectors (pMDLg/pRRE and pRSV-Rev) and one envelope plasmid
(pCMV-VSV-G) into HEK-293FT cells by lipofection. CHO-S and HEK293F cells were
then transduced with the packaged lentivirus particles. The infected cells were recovered
from the infection for 2 days or more and transferred to a shake flask for scaled-up culture.
The obtained stable cell pools were kept frozen before use.

4.5.3 Microsomal preparation
Cells were washed with Tris-buffered saline (25 mM Tris base, pH 7.4, 138 mM
NaCl, and 2.7 mM KCl) followed by a centrifugation at 2,000 × g for 5 min at 4oC. The
cell homogenates were prepared through resuspending the cell pellets in 25 mM Tris-Cl,
pH 7.4 and subjecting them to sonication. In order to remove cell debris or unbroken cells,
the total cell homogenates were exposed to centrifugation at 10,000 × g for 20 min.
Microsomes were prepared by ultracentrifugation of the supernatant at 100,000 × g for 1.5
hr and resuspending the resulting microsomal fraction in in 25 mM Tris-Cl, pH 7.4.
Microsomes (10 mg protein/ml) were stored at -70oC before use and their concentrations
were determined using the Bradford assay from Thermo Fisher Scientific (Waltham, MA).

4.5.4 Purification of UGT1A10
The purification of recombinant human UGT1A10-6xHis protein followed a
method described by Mika Kurkela,298 except that a HisPur™ Cobalt Resin from Thermo
Fisher Scientific (Waltham, MA) was utilized rather than a nickel-charged His Hi-Trap
column from GE Healthcare Life Sciences (Pittsburgh, PA). Briefly, microsomes were
suspended in an extraction buffer (25 mM Tris, pH 7.4, 500 mM NaCl, and 1% Triton X91

100) at 2 mg/ml of concentration followed by incubation for 10 min with shacking at 4oC.
The suspension was centrifuged at 100,000 × g for 1 hr. The resultant supernatant was
loaded onto a HisPur™ Cobalt Resin (Thermo Fisher Scientific) which has been preequilibrated with a washing buffer (25 mM Tris, pH 7.4, 500 mM NaCl, 0.05% Triton X100, and 50 mM imidazole). After extensive washing with the washing buffer, bound Histagged proteins were eluted by a stepwise gradient elution with imidazole in the presence
of 0.05% Triton X-100 and 150 mM NaCl. The eluents were analyzed by SDS-PAGE and
western blot for UGT1A. The concentration of purified UGT1A10-6xHis protein was
determined using the Bradford assay (Thermo Fisher Scientific).

4.5.5 Enzyme Activity Assays
Enzymatic glucuronidation of morphine or entacapone was tested under the
following assay conditions. All enzyme assays (100 µl final volume) contained 0.1 M
phosphate buffer, pH 7.4, 5 mM MgCl2, 5 mM saccharolactone, 5 mM UDPGA, and 100
μg of microsomal protein or 50 ng of purified UGT1A10-6xHis. Phospholipid (1 mg/ml)
was added to the assay mixtures containing the purified UGT1A10-6xhis. The
concentrations of aglycone substrate ranged from 0.1 to 20 mM (for morphine) or from 3
to 2000 μM (for entacapone). To initiate the reactions, UDPGA (5 mM in incubation) was
added to give a 100 µl final volume and then the reactions were incubated at 37oC with
shacking. The reaction time was adjusted such that no more than 10% of substrate was
depleted during reaction. Blank incubations were performed in the same manner, but
without UDPGA. The reaction was terminated with 100 µl glycine-HCl, pH 2, containing
1% (v/v) Triton X-100. The stopped reactions were centrifuged to pellet precipitated
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protein. The resulting supernatants were subjected to reverse-phase HPLC (RP-HPLC) on
a 5 µm C18 110 Å column (250 × 4.6 mm; Gemini) (Life Technologies) and RP-HPLC
was performed using the mobile phase consisting of 10% acetonitrile in 0.1% TFA and the
remaining substrate and resulting products were monitored by monitoring UV absorbance
at 230 nm (morphine and its glucuronide) or 315 nm (entacapone and its glucuronide). The
quantification was based on a standard curve prepared using an authentic standard
compound. All samples were prepared in duplicate or triplicate. GraphPad Prism 5.01
software (San Diego, CA) was utilized to analyze the kinetic data.

4.5.6 Hydrolysis by β-glucuronidase
The reaction mixture was centrifuged at 13,000 × g for 10 min and the resultant
supernatant was transferred to a new 1.5 ml microcentrifuge tube. β-Glucuronidase was
added to the supernatant at final concentration of 4 U/ml. The sample was incubated at
37°C for 2 hr before the reaction was terminated by 100 µl glycine-HCl, pH 2 containing
1% (v/v) Triton X-100.

4.5.7 Western blot assay
The levels of membrane-bound UGT1A10 protein in microsomes prepared from
human UGT1A10-6xHis overexpressing cell lines were measured by western blot analysis
using mouse anti-human UGT1A IgG obtained from Santa Cruz Biotechnology (Dallas,
Texas) (1:3000 dilution as described in the manufacturer’s instructions). HRP-conjugated
goat anti-mouse IgG (Santa Cruz Biotechnology) was used at 1:4000 as a secondary
antibody and UGT1A10 protein was finally detected by chemiluminescence using the
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SuperSignal West Dura Extended Duration Substrate from Pierce Biotechnology (Waltham,
MA). The levels of UGT1A10 were further quantified against a known amount of purified
UGT1A10-6xHis protein by densitometric scanning of the blots using Quantity One
software (Bio-Rad, Hercules, CA).
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Chapter Ⅴ. Development of a New Par-4 Entity with a Prolonged Duration of Action
Prostate apoptosis response-4 (Par-4) is one of tumor suppressors which protect
against neoplastic transformation. Par-4 is capable of inducing apoptosis selectively in
cancer cells through either the intrinsic or extrinsic pathway. Especially, extrinsic apoptosis
can be triggered by binding of extracellular Par-4 to cell surface GRP78 detected in various
tumor types. In this study, we found that recombinant Par-4 protein shows a limited serum
persistence in mice which may diminish its antitumor activity in vivo. Therefore, to
improve the performance of short-lived Par-4 protein, Par-4 was genetically conjugated to
a fragment crystallizable (Fc) of human IgG1 and expressed using the E. coli expression
system for large-scale production. The results of apoptosis assay demonstrated that E. coliderived novel Par-4 form (denoted as Fc(M1)-Par-4) retains significant proapoptotic
activity. In addition, the pharmacokinetic study of Fc(M1)-Par-4 in mice revealed that Fc
fusion leads to approximately 7-fold increase in the biological half-life of Par-4. We also
demonstrated that a prolonged circulating half-life by Fc fusion improves the ability of Par4 protein to suppress metastatic tumor growth in vivo.
A manuscript for the results described in this chapter will be submitted for
consideration of publication. Dr. Ziyuan Zhou and Xirong Zhang helped multiple blood
sample collections for the pharmacokinetic studies of Par-4 proteins in mice. Cell-based
anti-cancer activity assay and in vivo anti-tumor activity assay were performed by Dr.
Nikhil Hebbar and Nathalia Vitoria Pereira Araujo in the lab of Dr. Vivek M. Rangnekar.

5.1 The role of Par-4 as a tumor suppressor
Prostate apoptosis response-4 (Par-4) is a tumor suppressor protein expressed
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ubiquitously in a number of tissues. In 1994, the Par-4 gene was first discovered as an early
apoptotic gene in a rat prostate cancer cell line incubated with ionomycin for apoptotic cell
death.310-311 It was demonstrated that overexpression of Par-4 is sufficient to elicit apoptotic
cell death in most cancer cells.312 In line with this observation, the Par-4 gene has been
reported to be often deleted or significantly down-regulated in many different types of
cancer including gastric and pancreatic cancer,313 lymphoma,314 and neuroblastoma.306
The core domain of Par-4 (amino-acid residues 145-204 in human Par-4; and 137195 in rat Par-4), designated Selective for Apoptosis in Cancer cells (SAC), serves as the
effector domain responsible for its pro-apoptotic activity.315 Notably, this domain is 100%
conserved in mouse, rat, and human homologs, which implies that Par-4 plays a critical
role in the surveillance against tumors.315 Indeed, mature Par-4 protein and its SAC domain
both are capable to induce apoptotic cell death through both an intrinsic pathway (activated
by intrinsic stimuli such as biochemical stress or DNA damage, and mainly modulated by
Bcl-2 and Bax)316 and extrinsic pathway (activated in response to external stimuli such as
Fas ligand).317 At first, it was believed that Par-4 protein localizes and acts only in both the
cytoplasm and the nucleus for apoptosis induction,310, 318 but subsequent studies revealed
that Par-4 protein can be secreted to the extracellular space for action.311 Extracellular Par4 protein can induce apoptosis via caspase-3 and 8 activation when interacting with the
stress response protein, i.e. glucose regulated protein 78 (GRP78), expressed on the surface
of cancer cells.311 It has been also demonstrated that exposure to purified recombinant Par4 protein not only induce apoptosis in multiple types of cancer cells, but also inhibit tumor
growth in vivo.312, 320-324 Therefore, the current research of Par-4 related drug discovery has
focused on development of small-molecule drugs that can facilitate Par-4 secretion from
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normal cells for Par-4-dependent inhibition of tumor growth. Arylquin 1319 and chloroquine
(CQ), an anti-malarial drug,320 have been discovered as a strong inducer of Par-4 secretion
from normal or cancer cells.

5.2 The focuses of this research
However, the purpose of our study on Par-4 is different. In the present study, we
have engineered Par-4 to improve its in vivo stability, and investigated the potential
application of the engineered Par-4 protein as a novel protein therapeutic itself for cancer
treatment. We found that the tested recombinant Par-4 proteins stay in the circulatory
system of mice only for a very short period of time, and especially 6xHis-Par-4 protein
whose mass is below the threshold for glomerular filtration (≤ ~40 kD) undergoes much
rapid clearance from the blood. These results suggest a possibility that the therapeutic
efficacy of natural or recombinant Par-4 protein for cancer treatment increases with
enhanced in vivo performance. To address this possibility, Fc-fused Par-4 protein was
generated and produced using the E. coli expression system. It is demonstrated that Fcfusion enhances the performance of Par-4 in mice, which leads to increase in its potency to
inhibit metastatic tumor growth in vivo. These results also strongly support that the tumorsuppressing activity of secreted Par-4 is potentially diminished due to its limited serum
persistence in vivo. In this study, we discovered a novel Par-4 entity which is more suitable
for potentially promising Par-4-based protein or gene therapy, and developed a new method
for large-scale production of this therapeutically more valuable Par-4 entity.
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5.3 Results
5.3.1 The short serum persistence in vivo of recombinant Par-4 (Par-4)
In a previous report by Zhao et al.,321 it was demonstrated that the intravenous
administration of recombinant TRX-Par-4 or TRX-SAC protein (prepared in E. coli) in
immunocompetent C57/BL6 mice significantly suppressed lung metastasis of LLC1
(Lewis lung carcinoma line 1) cells in mice,321 which implies that both extracellular Par-4
and SAC proteins are capable of inhibiting metastatic tumor growth in vivo. Thioredoxin
(TRX) fusion protein is a frequently used tool to increase the solubility and expression of
mammalian proteins when they are expressed heterologously in E. coli.322 However, the
pharmacokinetic profiles of both TRX-Par-4 and TRX-SAC proteins have not yet been
studied despite of their considerable in vitro and in vivo anti-tumor activity against different
cancer cells.311, 320-321 Therefore, we first determined how long TRX-Par-4 or unfused Par4 protein can stay in the circulatory system of mice. To address this question, Par-4 protein
fused to the C-terminus of TRX or 6xHis-tag was prepared using the bacterial expression
system (TRX-Par-4 and 6xHis-Par-4, respectively; see Fig. 5.1A), and each purified
protein was then infused at the dose of 5 mg/kg in mice through tail vein injection. Blood
samples were collected at varying time points after protein injection and analyzed by
western blotting using anti-Par-4 antibody. The results revealed that both TRX-Par-4 (~50
kD) and 6xHis-Par-4 (~35 kD) proteins are quickly removed from the circulatory system.
(Fig. 5.1B & C) TRX-Par-4 concentration decreased in vivo at a relatively slower than that
of 6xHis-Par-4, with the former able to be observed up to 90 min after i.v. injection, while
6xHis-Par-4 could be detected at very low signal up to 30 min. These findings suggest the
possibility that the in vivo anti-tumor activity of Par-4 protein is limited or underestimated
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due to its short circulating half-life. Therefore, we decided to investigate the hypothesis
that extended exposure due to improved biological half-life by Fc fusion enhances in vivo
antitumor activity of Par-4 protein in a mouse model for tumor metastasis.

Figure 5.1 The limited serum persistence of recombinant Par-4 proteins in mice. (A) SDSPAGE of the purified TRX-fused or hexa-histidine tagged Par-4 (TRX-Par-4 and 6xHisPar-4, respectively). Mice were injected intravenously with 5 mg/kg TRX-Par-4 or 6xHisPar-4. Relative serum concentrations of TRX-Par-4 (B) and 6xHis-Par-4 (C) were
evaluated at periodic intervals by western blotting. The recombinant Par-4 proteins were
detected with antibody against Par-4 and visualized by chemiluminescence. The light chain
of mouse IgG1 was used as an internal loading control. The two panels are representative
blots of two mice.

5.3.2 Development of a method for large-scale production of Fc-fused Par-4
We first designed a novel Par-4 entity with a prolonged duration of action. A great
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effort was also made to obtain a sufficient amount of the protein material for in vivo
characterization. Our protein engineering in this study started from rat Par-4, rather than
human Par-4, because the engineered novel Par-4 entity would be tested in vivo using
rodents (mice and rats).

5.3.2.1 Design of a new Par-4 entity with a prolonged half-life
The therapeutic efficacy of a therapeutic protein drug can be greatly increased by
improving its pharmacokinetic profile.28, 49-54 Protein fusion with the Fc region of human
IgG1 (IgG Fc) is one of the most commonly used strategies to prolong the duration of
action of protein therapeutics.56-57 An A1Q/C6S/C12S/C15S/P24S human Fc variant
(denoted as Fc(M1) for convenience) is a monomeric Fc variant and has been successfully
utilized to improve the half-life time of abatacept, a therapeutic antibody drug.323 To extend
the biological half-life of Par-4, the gene was first genetically fused to the C-terminus of
Fc(M1). The leader peptide sequence of mouse Ig kappa-chain was then added to the Nterminus of the fusion gene to facilitate its secretion from the cytosol to the extracellular
space (Fig. 5.2). The resultant gene of Fc(M1)-Par-4 (~70 kD) was first prepared using the
CHO expressing system to obtain the amount of protein sufficient for the in vivo
characterization study of the protein. Purification of the E. coli-derived soluble Fc(M1)Par-4 protein was performed using protein A affinity chromatography (Fig. 5.4).

Figure 5.2 The schematic presentation of the fusion protein of Par-4 to Fc(M1). ‘ss’
represents the leader peptide sequence of mouse IgG kappa-chain.
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5.3.2.2 Passage number-related effects on stable CHO-S cells expressing Fc-fused Par4
As described in the methods section, a lentiviral vector-mediated gene transfer
method was employed to generate stable CHO lines for efficient production of recombinant
Par-4 protein. However, contrary to our expectations, we found that the generated cell lines
at high passage numbers underwent alterations in the efficiency of Fc(M1)-Par-4
production, compared to lower passage cells. The expression levels of the recombinant Par4 protein rapidly and gradually decreased as the passage number increased (Fig. 5.3). In
fact, for more rapid establishment of a stable cell line, our protocol for generation of stable
CHO cells does not include any antibiotics selection process which is usually required for
screening and selecting a more stable and productive clone from the cell population
transduced with recombinant lentiviral particles. Considering that the growth rate of the
resulting transduced pooled cell population was slightly decreased when compared to that
of naïve CHO cell, the cell viability or proliferation activity of the transduced CHO cells
in the pooled cell population might be more specifically and negatively affected by the
combinational activity of extracellular and intracellular recombinant Par-4 protein.
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Figure 5.3 The secretion levels of a recombinant Par-4 protein to the culture media. Each
10 µl of culture medium was analyzed by western blot for Par-4.

5.3.2.3 Expression of Fc(M1)-Par-4 protein by transient transfection
We were able to obtain a sufficient amount of Fc(M1)-Par-4 protein for its
pharmacokinetic study in mice by transient gene expression in CHO‐S cells using a
commercially available transfection reagent (TransIT-PRO™), but the obtained quantity
was still not sufficient for a planned in vivo antitumor activity study (Fig 5.4). In reality,
transient gene expression using a commercially available transfection agent such as
TransIT-PRO, Cellfectin, and Lipofectamine is not generally considered a suitable method
for a large-scale protein production mainly due to the high cost of the reagents.
Polyethylenimine (PEI) has been widely used as a transfection reagent largely due
to its low cost, despite of its non-negligible cytotoxicity. PEI is a cationic polymer which
can introduce nucleic acids such as DNA or RNA into mammalian cells with the
polymer.324 PEI condenses DNA molecules into positively charged particles that interact
favorably with the negatively charged phospholipid membrane of cell surface.
Consequently, the complexes of DNA and PEI are internalized into cells by endocytosis
and the DNA is then released into the cytosol.325 Indeed, a number of cell lines are proven
to be efficiently transfected with PEI. Especially, CHO-S and HEK 293 cells have
displayed a relatively higher recombinant protein expression than other cell lines.326
Therefore, to test the possibility that PEI can be utilized for large-scale production of
Fc(M1)-Par-4 protein, the gene was transiently expressed in CHO-S cells using either PEI
or TransIT-PRO™ for comparison. As shown in Fig. 5.5, a substantially decreased
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production of Fc(M1)-Par-4 protein was observed in the CHO cells transfected with PEI,
compared to that of the CHO cell transfected with TransIT-PRO™. Interestingly, it was
also observed that the CHO cells transfected with PEI or TransIT-PRO™ show a similar
level of 6xHis-Par-4 expression. Given that Fc-fused Pat-4 protein might be exposed to a
more complicated modification process than 6xHis-Par-4 protein in CHO cells because of
its Fc part which requires for proper post-translational modification, the difference in a way
of delivering DNA to cells between PEI or TransIT-PRO™ seems to specifically affect Fcfused-Par-4 expression in CHO cells, but not significantly affect the expression of 6xHistagged one. Overall, these data indicate that it is not suitable to use PEI for Fc(M1)-Par-4
expression, but it seems okay to use the reagent for 6xHis-Par-4 expression.

Figure 5.4 SDS-PAGE of the purified Fc(M1)-Par-4.
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Figure 5.5 Recombinant Par-4 protein is expressed at a scale of 100 ml using each of
TransIT-PRO™ and PEI. Each bar represents the average of triplicates and the values are
expressed as mean ± S.D.

5.3.2.4 Expression of recombinant Par-4 proteins using a bacterial expression system
Fc(M1)-Par-4 (~70 kD) was then prepared using the E. coli expressing system to
obtain the amount of protein sufficient for the in vivo characterization study of the protein.
Purification of the E. coli-derived soluble Fc(M1)-Par-4 protein was performed using
protein A affinity

chromatography,

followed

by

an

additional

ion-exchange

chromatographic step to obtain the purity required for a following in vivo characterization
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study. (Fig. 5.6B & C)

Figure 5.6 Preparation of Fc(M1)-Par-4. (A) The schematic presentation of Fc(M1)-Par-4.
(B) Western blot analysis of Par-4 protein in bacterial extract transformed with pET22b(+)/6xhis-Par-4 and induced with IPTG. The soluble fraction (S) of the bacterial extract
was separated from the insoluble fraction (I) by centrifugation before immunoblotting. (C)
SDS-PAGE of the purified Fc(M1)-Par-4 protein. Soluble Fc(M1)-Par-4 protein was
isolated by protein A chromatography (Protein A) followed by an additional ion-exchange
chromatographic step (Ion exchanger) to achieve the purity required.
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5.3.2.5 Practical protocols for production of high yields of Fc-fused Par-4 protein using
the E. coli expression system
Although the established purification system yielded proteins of high purity, the
yield after purification was still low (~1 mg/L bacterial culture for ~0.2 mg/L bacterial
culture for Fc(M1)-Par-4). This low yield is mainly due to the formation of insoluble
aggregates of Fc-fused Par-4 protein during high level expression in bacteria, and more
complicated purification process. To obtain a higher quantity of Fc-fused Par-4 protein
using the E. coli expression system, efforts have been focused on increasing production of
the recombinant Par-4 protein.
1) Codon optimization
The efficiency of heterologous protein expression in bacteria can be attenuated by
biased codon usage. The approaches typically used to overcome this issue are site-directed
mutagenesis to replace rare codons with other synonymous codon frequently used in
bacteria, or the use of specialized cell lines supplying rare codon tRNAs such as Rosetta
(DE3)TM.327 Our in silico studies revealed that the open reading frame of Fc(M1)-Par-4
mRNA contains six rare codons in E. coli that may decrease protein expression (Fig. 5.7).
However, we found that Fc(M1)-Par-4 protein production was not increased in Rosetta
(DE3)TM cell (Fig. 5.8), which suggests that these six rare codons are not rate-limiting for
protein synthesis.
In fact, the translation efficiency of mRNA is affected by a number of factors
including codon adaptability (e.g. synonymous codon changes), the structure of mRNA,
and different cis-acting elements involved in transcription and translation. With the help of
a free online tool that takes these factors into consideration (built from Integrated DNA
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Technologies), the full mRNA sequence of Fc(M1)-Par-4 was optimized for high yield
production in E. coli and finally its expression was increased by a factor of about 3 after
codon optimization (Fig. 5.9).

Figure 5.7 Rare codons found in the coding region of Fc(M1)-Par4 gene. The rare codons
are indicated by red arrow.

Figure 5.8 SDS-PAGE analysis of Fc(M1)-Par-4 in the E. coli BL21 (DE3) and Rosetta
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(DE3) transformed with pET-22b(+)/Fc(M1)-Par-4. Each 10 µg of soluble bacterial extract
was loaded per lane.

Figure 5.9 Effects of computational codon optimization of Fc(M1)-Par-4 gene on its
bacterial expression. Each 10 µg of soluble bacterial extract was loaded per lane.

2) High cell-density culture of E. coli
Terrific Broth (TB) is a nutritionally enriched medium developed by TARTOFF and
HOBBS (1987) to increase yields in recombinant strains of E. coli. TB consists of tryptone,
yeast extract, glycerol, and potassium phosphate. Excess potassium phosphate molecules
keep the pH of the cell culture medium in a favorable range for the growth of E. coli, which
allows cells to be protected against cell death due to decrease in pH. In addition, more
nutrition (380% more yeast extract and 20% more tryptone than LB) in TB supports the
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high cell-density growth of E. coli which is generally related to the elevated yield of
recombinant protein production.
We have evaluated the process for Fc(M1)-Par-4 expression in the E. coli BL21
(DE3) transformed with pET-22b(+)/Fc(M1)-Par-4 in TB medium. First, to obtain overall
growth rate curves of the transformed E. coli for two temperatures (18°C or 37°C) and to
determine the time until exponential growth is observed (Absorbance at 600 nm (Abs600,
also known as OD600) = 0.7) at these temperatures in a given condition, the transformed
cells were cultivated at either 18°C or 37°C and monitored by measuring Abs600 every 1 h.
The results indicate that the transformed E. coli reached an OD600 of 0.7 in about 7.5 hours
at 18°C while it took 4 h to reach a similar absorbance at 37°C. The cell growth reaches
saturation phase within 11 h at 37°C, but it took almost 18 h to reach the same absorbance
at 18°C (Fig. 5.10).
Based on this information, we designed experiments to assess the effect of cell
growth for induction (Absind) on cell growth and Fc(M1)-Par-4 protein expression in the E.
coli BL21 (DE3) transformed with pET-22b(+)/Fc(M1)-Par-4. For this, the transformed E.
coli was cultured at 18°C. Fc(M1)-Par-4 expression was induced at an Abs600 of 0.7 or 2.0
by the addition of IPTG to a final concentration of 0.5 mM, followed by incubation for 10
h. The results reveal that the non-induction control group yields higher cell concentrations
than the other two IPTG induction groups, which suggests that expression of Fc(M1)-Par4 is toxic to the recombinant strain of E. coli. It was also observed that induction at
Absind 2.0 leads to substantial increase in cell growth, compared to induction at Absind 0.7
(Fig. 5.11). However, no noticeable difference was observed in recombinant protein
expression when Absind 2.0 was compared with 0.7 (Fig. 5.12). These data indicate that
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total Fc(M1)-Par-4 protein production can increase if IPTG induction is done at a higher
absorbance in the exponential phase.

Figure 5.10 Growth curves of the E. coli BL21 (DE3) transformed with pET22b(+)/Fc(M1)-Par-4. Cell growth at 37°C in LB at 220 rpm, or at 37°C or 18°C in TB at
350 rpm. Each dot represents the average of duplicates and its values are expressed as the
mean ± standard deviation.

Figure 5.11 Comparison between IPTG-induced and uninduced growth of the transformed
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E. coli BL21 (DE3) at 18°C in TB at 350 rpm. Each dot is the representative of the average
of duplicates and its values are expressed as the mean ± standard deviation.

Figure 5.12 Effects of the induction variables (OD600) on the expression of Fc(M1)-Par4 in the E. coli BL21 (DE3) transformed with the gene.

5.3.3 E. coli-derived Par-4 proteins induce apoptosis in cancer cells
Before in vivo characterization of the purified recombinant Par-4 proteins, we first
determined whether Fc fusion to the N-terminus of Par-4 diminishes its proapoptotic
activity or not. To address this question, E0771 (murine breast cancer cell line) cells were
treated with either 100 nM 6xHis-Par-4 or Fc(M1)-Par-4 protein, followed by incubation
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for 24 h. Storage buffer (50 mM Hepes, 20% sorbitol, 1 M glycine, pH 7.4) was used as a
vehicle control. It was observed that Fc(M1)-Par-4 and 6xHis-Par-4 proteins induced a
similar level of apoptosis in E0771 cells in a given treatment condition (Fig. 5.13), which
supports that anti-cancer activity of Par-4 is not significantly altered by Fc fusion to its Nterminus. This observation is very consistent with the findings of Zhao et al.321 using TRXPar-4.

Figure 5.13 Recombinant Par-4 elicits apoptosis in E0771 (murine breast cancer cell line)
cells. (A) SDS-PAGE of the purified Fc(M1)-Par-4. (B) The cells were treated with vehicle
(V), or purified 6xHis-Par-4 (6H) or Fc(M1)-Par-4 (Fc) (100 nM each). 24 h after treatment
the cells were scored for apoptosis by immunocytochemistry (ICC) for caspase 3 activity.
Results represent the average of triplicates and the values are expressed as mean ± S.D.
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Asterisk (*) indicates the difference is statistically significant (p < 0.05) by Student’s t-test.
Dr. Nikhil Hebbar in the lab of Dr. Vivek M. Rangnekar provided this figure.

5.3.4 Characterization of the in vivo profiles of recombinant Par-4
To examine whether the protein fusion to an IgG Fc region really prolongs the
biological half-life of Par-4 protein, a pharmacokinetic study was carried out in mice. The in
vivo data were based on intravenous (i.v.) injection of each protein in the tested mice. The
generated PK data are depicted in Fig. 5.14, and the biological half-lives obtained are
summarized in Table 5.1. The results revealed that both Fc(M1)-Par-4 proteins prepared from
CHO and E. coli cells have a substantially longer biological half-lives (up to ~23.8 h) than
that (~3 h) of 6xHis-Par-4 protein. Aglycosylated Fc(M1)-Par-4 protein displays a biological
half-life (~20.3 h) which is comparable to that of CHO-cell derived Fc(M1)-Par-4 protein
(~23.8 h).

113

Figure 5.14 Serum concentration (%) versus time profiles of recombinant Par-4 proteins
in mice. CHO cell-derived Fc(M1)-Par-4 (□), E. coli-derived Fc(M1)-Par-4 (■) or E. coliderived 6xHis-Par-4 (●) was administered via i.v. infusion at 5 mg/kg and the serum Par-4
protein concentrations were determined by ELISA. Results represent the average of
triplicates per group and shown as mean ± standard error.

Table 5.1 The determined biological half-lives of recombinant Par-4 proteins in mice
Protein

Prepared from

t1/2

6xHis-Par-4

E. coli

~3 hr

Fc(M1)-Par-4

E. coli

~20.3 hr

Fc(M1)-Par-4

CHO-S

~23.8 hr
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5.3.5 In vivo characterization of recombinant Par-4 proteins for their potency in
inhibiting metastatic tumor growth
To examine whether longer exposure due to half-life extension by Fc fusion
improves in vivo antitumor activity of Par-4, we evaluated how efficiently Fc(M1)-Par-4
and 6xHis-Par-4 proteins inhibit lung metastasis of E0771 breast cancer cells in
immunocompetent C57/BL6 mice. To address this question, the cells (1.5 × 105 cells) were
injected through tail vein and then 250 µg E. coli-derived 6xHis-Par-4 or Fc(M1)-Par-4
was administered intravenously every other day for 12 days (total of 1500 µg of
protein/mouse). It was observed that both Fc(M1)-Par-4 and 6xHis-Par-4 proteins
significantly suppressed metastatic tumor growth in vivo compared to vehicle-treated
control, but with no statistic difference between the two protein-treated groups in a given
treatment condition (Fig. 5.15A). However, considering that the molecular weight of
Fc(M1)-Par-4 protein (~70 kD) is approximately 1.7-fold higher than that of 6xHis-Par-4
protein (~35 kD), the mice have not been treated with equivalent molar concentrations of
recombinant Par-4 proteins. This may suggest that Fc(M1)-Par-4 protein than 6xHis-Par-4
protein indeed would be more potent in inhibiting metastatic tumor growth in vivo, but the
difference in their potency might become less evident at the high dose.
Therefore, to address this question, we further determined if the in vivo anti-tumor
activity of Fc(M1)-Par-4 protein is diminished as the dose decreases. According to the data
obtained (Fig. 5.15B), a 70%-reduced dose of Fc(M1)-Par-4 protein (75 µg/injection) also
induced substantial inhibition of lung metastasis in mice induced by E0771 breast cancer
cells. Considering that lung metastasis by E0771 breast cancer cells was not significantly
reduced at the low doses (≥ 250 µg/injection) of TRX-Par-4 in the previous studies,321 these
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results indicate that Fc-fusion has improved the potency of Par-4 protein in inhibiting in
metastatic tumor growth vivo.

Figure 5.15 Recombinant Par-4 protein suppresses the metastatic growth of tumor (E0771).
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The cells (1.5 × 105 cells) were administered into tail vein in B6C3H mice (n=5). (A) 5 h
after administration, vehicle, or 250 µg purified 6xHis-Par-4 (His-Par) or Fc(M1)-Par-4
(Fc-fuse-Par-4) was injected through tail vein every alternate day for 12 days (total of
1500 µg of protein/mouse). (B) 5 h after administration, vehicle, or 150 or 75 µg purified
Fc(M1)-Par-4 was injected through tail vein every alternate day for 12 days (total of 900
and 450 µg of protein/mouse, respectively). Four weeks later, the mice were euthanized,
and the number of the lung nodules were then counted. The data are expressed as the mean
± SEM. The single and double asterisks indicate p < 0.05 and p < 0.01, respectively.

5.4 Discussion
In 2011, Zhao et al.321 showed that lung metastasis in immunocompetent mice
induced by LLC1 lung cancer cells was substantially inhibited by the intravenous injection
of 500 µg recombinant TRX-Par-4 or TRX-SAC protein. However, the quantity of Par-4
protein used in the animal study seems substantially higher than usual because, assuming
that the body weight of an adult mouse is 30 mg, the protein dose used can be calculated
to be around 17 mg/kg (of body weight) which is comparable to a human dose of
approximately 1000 mg per person for a typical body weight of 60 kg. Obviously, the
protein dose of 1000 mg per person would be too high for practical clinical use. Both TRXPar-4 and TRX-SAC proteins have proven their reasonable (and probably therapeutically
valuable) in vitro and in vivo anti-cancer activity,311, 320-321 but to my best knowledge their
pharmacokinetic profiles have not yet been studied. This led us to examine whether TRXPar-4 or unfused Par-4 protein has a sufficiently long serum persistence required for proper
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in vivo activity. Our results showed that both TRX-Par-4 and 6xHis-Par-4 proteins stay in
the circulatory system only for very short periods of time (˂ 120 min for TRX-Par-4 and ˂
60 min for 6xHis-Par-4) (Fig. 5.1), which suggests the possibility that the anti-tumor
efficacy in vivo of Par-4 protein has been underestimated due to its short circulating halflife. In addition, considering that low-molecular-weight drugs whose mass are below the
threshold for glomerular filtration (≤ ~40 kD) usually undergo rapid clearance from the
blood,328-332 our data suggest that the relatively longer serum persistence of TRX-Par-4
protein (~50 kD) than that of 6xHis-Par-4 protein (~35 kD) would be largely attributed to
its higher molecular weight than the threshold, and that natural Par-4 protein (~35 kD)
released from cells to the blood stream might be short-lived due to its limited molecular
size.
Par-4 was engineered to improve its pharmacokinetic performance so that it shows
enhanced therapeutic response in mice. For this reason, Par-4 protein was genetically
conjugated to the C-terminus of Fc(M1), a human IgG Fc variant. Fusion to IgG Fc is a
preferably used method to extend the biological half-life of therapeutically valuable protein
by exploiting the FcRn-mediated recycling mechanism.66-68 The endothelial cellular
neonatal Fc receptor (FcRn) has a critical role in maintaining the high circulating levels of
IgG.59-60 Indeed, IgG has a prolonged circulating half-life of 21 days in human mainly due
to FcRn-mediated recycling that protects against intracellular endocytic-lysosomal
degradation.61-62 IgG Fc strongly interacts with FcRn in the acidic endosomal
compartments after IgG is internalized into endocytic vesicles.63 The receptor-bound
proteins are then returned to the cell membrane for extracellular release, whereas other
serum proteins in the vascular endothelium are eventually degraded by the endocytic-
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lysosomal system.64-65 Like IgG, Fc-fusion proteins can take the advantage of the FcRnmediated recycling process for half-life extension.
In the present study, our effort was also made to produce a sufficiently large amount
of recombinant Par-4 proteins for animal studies. The bacterial expression system was
employed for large-scale production of Fc(M1)-Par-4. The E. coli expression system is
considered one of preferable choices for large-scale production of therapeutic protein drugs
mainly because of greater cost-effectiveness and easier cultivation of bacteria, compared
to the CHO or HEK293 expression system. However, the deficiency of mechanisms for
protein post-translational modification in bacterial cells has limited the use of bacteria for
production of therapeutic protein agents that require proper modification for functional
activity or stability. Therefore, one question to be asked about this approach is: how E. coliderived Fc-fused Par-4 protein retains the functional activity and circulating half-life
comparable to those of the fusion protein prepared from mammalian cells. However, there
is a good possibility that aglycosylated Fc-fused Par-4 protein still can meet these
requirements to be an effective therapeutic for cancer. First, previous studies have
demonstrated that an aglycosylated IgG1 prepared from E. coli retains a sufficiently long
in vivo half-life comparable to that of mammalian cell-derived immunoglobulins, and that
aglycosylated and glycosylated antibodies show equivalent in vitro binding to FcRn.333-335
These observations indicate that, in the case of immunoglobulin in vivo half-life, the motifs
within the Fc portion responsible for the interaction with FcRn do not rely on posttranslational modification including glycosylation. Second, it was already demonstrated
that Par-4 protein prepared from bacteria retains reasonable in vitro and in vivo anti-tumor
activity,321 which implies that the post-translational modification of Par-4 is not critical for
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its functional activity.
Although only less than 20% of Fc(M1)-Par-4 protein was expressed in E. coli as a
soluble and intact from (Fig. 5.6B), we were able to obtain the amount of the recombinant
Par-4 protein sufficient for the required in vitro and in vivo studies using the E. coli
expression system. We also found that the E. coli-derived Fc(M1)-Par-4 protein not only
retains considerable in vitro anti-cancer activity after purification (Fig. 5.13), but also has
approximately 7 times longer biological half-life than 6xHis-Par-4 (Fig. 5.14 & Table 5.1).
These results suggests that Fc fusion extends the biological half-life of Par-4 by both
increasing its size high enough to escape glomerular filtration (≤ ~40 kD) and implementing
protection against cellular endolysosomal degradation. As the next step, it was further
determined if Fc(M1)-Par-4 protein has improved antitumor activity in a mouse model for
lung cancer metastasis induced by murine breast cancer cells. The results revealed that
Fc(M1)-Par-4 protein is capable to substantially reduce lung metastatic growth in vivo at
the low doses where TRX-Par-4 protein did not show significant in vivo anti-tumor activity
in the same mouse model used in the previous studies321 (Fig. 5.15). These results strongly
support that increased exposure to Par-4 due to half-life extension improves the therapeutic
efficacy of Par-4 for cancer. Overall, our study also shows a good possibility that the E.
coli expression system can be utilized for the production of a therapeutically valuable form
of Par-4 protein.

120

5.5 Experimental details
5.4.1 Cloning, expression and purification of 6xHis-Par-4 and Fc(M1)-Par-4
The E. coli expression system
Bacterial expression constructs for TRX-Par-4, 6xHis-Par-4, and Fc(M1)-Par-4
were produced by subcloning each gene into pET-22b(+) vector. The constructs TRX-Par4 was prepared by subcloning the rat Par-4 sequence in frame with thioredoxin cDNA
(TRX) in vector pThio-His (Invitrogen Corporation, Carlsbad, CA) as described in a
previous reported by Burikhanov et al.311 E. coli BL21 (DE3) StarTM cells (Thermo Fisher
Scientific, Waltham, MA) were transformed with each construct and induced with 0.5 mM
IPTG (Sigma-Aldrich, St. Louis, MO). The cells were harvested 10 h after IPTG induction.
The cells were then washed with Tris-buffered saline (25 mM Tris base, pH 7.4, 138 mM
NaCl, and 2.7 mM KCl) followed by a centrifugation at 2,000 × g for 5 min at 4oC. The
cell homogenates were prepared through resuspending the cell pellets in 25 mM Tris-Cl,
pH 7.4 and subjecting them to sonication. In order to remove cell debris or unbroken cells,
the total cell homogenates were exposed to centrifugation at 10,000 × g for 20 min.
For purification of TRX-Par-4 or 6xHis-Par-4 protein, the resultant supernatant was
loaded onto a HisPur™ Cobalt Resin (Thermo Fisher Scientific) which has been preequilibrated with a washing buffer (25 mM Tris, pH 7.4, 500 mM NaCl, 0.05% Triton X100, and 50 mM imidazole). After extensive washing with the washing buffer, bound Histagged proteins were eluted by a stepwise gradient elution with imidazole in the presence
of 150 mM NaCl.
For purification of Fc(M1)-Par-4 protein, the resultant supernatant was loaded onto
a rmp Protein A Sepharose Fast Flow (GE Healthcare Life Sciences) pre-equilibrated with
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20 mM Tris⋅HCl (pH 7.4). Then, the mixture was packed in a column and washed with 5
column volume (CV) of 20 mM Tris⋅HCl (pH 7.4) containing 200 mM NaCl until an OD280
< 0.02 was achieved; then the protein was eluted by 50 mM sodium acetate, pH 4.0,
containing 200 mM NaCl. For buffer exchange, the eluate was dialyzed in 20 mM Tris⋅HCl
(pH 7.4) by Millipore Centrifugal Filter Units. The protein solution was then loaded onto
a Q-Sepharose Fast Flow (GE Healthcare Life Sciences, Pittsburgh, PA) pre-equilibrated
with 20 mM Tris⋅HCl, pH 7.4, for the second-round chromatographic separation. Fc(M1)Par-4 protein was eluted from the Q-Sepharose column with a stepwise gradient of NaCl
(100–800 mM). For buffer exchange, the eluate was dialyzed in storage buffer (50 mM
Hepes, 20% sorbitol, 1 M glycine, pH 7.4) by Millipore Centrifugal Filter Units. The entire
purification process was performed in a cold room at 8°C and the purified proteins were
stored at −80°C until the activity tests. Their purity was analyzed by SDS-PAGE on a 4−12%
NuPAGE Novex Bis-Tris gel (Life Technologies).
The CHO expression system
Mammalian expression constructs for Fc(M1)-Par-4 were produced by subcloning
each gene into pCMV-MCS vector. CHO-S cells were incubated in FreeStyle CHO
Expression Medium (Life Technologies) with 8 mM l-glutamine (Life Technologies) at
37°C in a humidified atmosphere with 8% CO2 and transfected with gene expression DNA
constructs encoding the protein of interest using the TransIT-PRO Transfection Kit (Mirus
Bio LLC, Madison, WI)) when the number of the cells reached 1.0 × 106 cells/mL. The
culture medium was harvested 6 days after transfection. Fc(M1)-Par-4 protein secreted into
the culture medium was purified by protein A affinity chromatography. After removing
cells by centrifugation, the cell-free culture medium was mixed with rmp Protein A
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Sepharose Fast Flow (GE Healthcare Life Sciences) pre-equilibrated with 20 mM Tris⋅HCl,
pH 7.4, and incubated for overnight at 6°C with occasional stirring. Then, the suspension
was packed in a column and washed with 5 column volume (CV) of 20 mM Tris⋅HCl, pH
7.4, containing 200 mM NaCl until an OD280 < 0.02 was achieved; then the protein was
eluted by adjustment of the pH and salt concentration. The eluate was then dialyzed in
storage buffer (50 mM Hepes, 20% sorbitol, 1 M glycine, pH 7.4) by Millipore Centrifugal
Filter Units. The entire purification process was conducted on ice and the purified Par-4
proteins were stored at −20°C until use. Their purity was analyzed by SDS-PAGE on a
4−12% NuPAGE Novex Bis-Tris gel (Life Technologies).

5.4.2 Western blot
Recombinant Par-4 proteins in bacterial extract transformed with pET22b(+)/6xhis-Par-4 or pET-22b(+)/Fc(M1)-Par-4 were analyzed by western blot using goat
anti-rat Par-4 IgG obtained from Santa Cruz Biotechnology (Dallas, Texas) (1:3000
dilution as described in the manufacturer’s instructions). Pre-adsorbed, HRP-conjugated
anti-goat IgG (Santa Cruz Biotechnology) was used at 1:4000 as a secondary antibody and
Par-4 protein was finally detected by chemiluminescence using the SuperSignal West Dura
Extended Duration Substrate from Pierce Biotechnology (Waltham, MA).

5.4.3 Immunocytochemistry and apoptosis analysis
Cells in chamber slides were exposed to 100 nM purified Fc(M1)-Par-4 or 6xHisPar-4. 24 h after treatment the cells were subjected to immunocytochemistry (ICC) using
the indicated anti-caspase 3 IgG and then stained with the appropriate secondary antibody
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conjugated to Alexa Fluor-488 (green fluorescence) or Alexa Fluor-594 (red fluorescence)
(Molecular Probes). Apoptotic nuclei were identified by TUNEL assay, caspase-3
immunostaining, or 4, 6-diamidino-2-phenylindole (DAPI) staining. A total of three
independent experiments were performed; and approximately 300 cells were scored in each
experiment for apoptosis under a fluorescent microscope, as described previously.336

5.4.4 Pharmacokinetics studies in mice
ELISA for Par-4
Mice (n=3) were injected with each recombinant Par-4 protein or saline through the
tail vein at a dose of 5 mg/kg of body weight. Blood samples were then obtained by needle
puncture of the saphenous vein. Approximately 15-30 µL of blood was collected into a
heparin-treated capillary tube at differing time points after protein injection. The plasma
was separated from the collected blood samples by centrifugation (15 min, at 5,000 × g).
200 ng of plasma protein in 100 μl 0.05M PBS, pH 7.4, was immobilized in a 96 well flatbottomed EIA plate (Corning) at 4 °C overnight (or 37 °C for 2 h). The liquid was dumped
from the plates and the rest was drained on paper towel. Coated wells were blocked with
blocking buffer (0.05M PBS, pH 7.4, containing 1 mg/ml casein) (250 μL/well) at RT for
30 min. After washing twice with washing buffer (0.05M PBS, pH 7.4) (250 μL/well), 100
μl of goat anti-rat Par-4 IgG (Santa Cruz Biotechnology) in blocking buffer was added to
each well at a range of concentrations. The plate was then covered with an adhesive plastic
and incubated, with continual shaking, at RT for 1 h. After washing three times with
washing buffer, pre-adsorbed, HRP-conjugated secondary antibody (anti-goat IgG-HRP)
(70 μl/well), diluted with blocking buffer at a ratio of 1:30,000, was added into each well
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and incubated at RT for 1 h on a shaker. The wells were then washed three times with
washing buffer (250 μl/well) before 250 μl TMB substrate was added to the wells. The
ELISA plate was kept in the dark until the desired color develops. The reaction was stopped
with 100 µL of 0.5 M HCl. The absorbance (= the developed blue color) was measured at
450 nm using a microplate reader. All measurements were performed in triplicate or
quadruplicate. The obtained PK data (time dependent enzyme concentrations) ([E]t) were
fitted to a double-exponential equation
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by GraphPad Prism 5.01 software:

[ E ]t = Ae − k1t + Be − k 2t , which explains both the distribution process (the fast phase,

associated with k1) and the elimination process (the slow phase, associated with k2) of the
Fc-fused CocH3 protein in animals. The t1/2 associated with the elimination rate
constant k2 of the fusion protein is known as the biological t1/2 or elimination t1/2.

Western blot for Par-4
The plasma protein was analyzed by western blot for Par-4, as described above.

5.4.5 Lung metastasis of E0771 cells
The E0771 cells (1.5 × 105 cells) were administered into tail vein in
immunodeficient B6C3H mice (n=5). 5 h after administration, 6xHis-Par-4 or Fc(M1)- Par4 was injected through tail vein every alternate day for 12 days (total of 1500 µg of
protein/mouse). Four weeks later, the mice were euthanized, and the lungs were
photographed. The number of the lung nodules were then counted.
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5.4.6 Statistical analysis
Statistical analyses were performed with the Statistical Analysis System Software
Version 9.2 (SAS Institute, Cary, NC). Unless stated explicitly otherwise, one-way ANOVA
with post hoc analysis was utilized for the statistical analysis.
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Chapter ⅤI. Conclusions and Future Directions
6.1 Cocaine abuse treatment
The first of our designed CocHs, i.e. CocH1, has been proven safe and promising
for use in animals and humans in preclinical and clinical studies.84, 199 However, a Phase II
clinical trial of Albu-CocH1 for cocaine addiction treatment revealed that its actual
therapeutic value for cocaine addiction treatment is still limited mainly due to its
insufficiently long biological half-life which is 43-77 h in humans84 or ~8 h in rats.198
The first part of my dissertation was focused on the development of a new CocH
entity which is able to deliver a greater catabolic activity within the human body so that
our CocH-based therapy for human cocaine addiction fits within the desirable once-weekly
or longer dosing schedule. We found that Fc fusion greatly extended the serum persistence
in vivo of CocH3 whose catalytic efficiency against cocaine is about 2-fold higher than that
of CocH1. Enhanced FcRn binding by Fc engineering further improved its biological halflife in rats. Our rodent studies also demonstrated that the new CocH entity efficiently
protected animals from the physiological and psychostimulant effects of cocaine, and more
importantly, the anti-cocaine effect delivered by the enzymes remained in the circulatory
system for prolonged periods of time. As for the next step, the potential efficacy of longterm administration of the enzyme as a treatment for cocaine addiction must be evaluated
further. Given that many preclinical studies already have shown that therapies using a
cocaine-metabolizing enzyme can significantly reduce cocaine-primed reinstatement and
cocaine-self-administration,192-195 the use of our new CocH entity with a prolonged
duration of action will allow us to determine if this catalytic treatment can decrease the
reinforcing action of cocaine for a sufficient period required to achieve long-term
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extinction of drug-craving behavior in animals and humans.
Since heroin is one of the most frequently abused drugs with cocaine, in the second
part of this dissertation we kinetically compared human recombinant AChE, BChE, and
CocH1 with the aim to examine their catalytic efficiencies against heroin and 6-MAM.
This allowed us to assess the interaction between cocaine and heroin or cocaine and 6MAM in their hydrolysis reactions catalyzed by CocH1 in comparison with human
enzymes AChE and BChE. According to the results obtained, both AChE and BChE can
catalyze 6-MAM hydrolysis to morphine, with relatively lower catalytic efficiency
compared to the corresponding enzyme catalyzing heroin hydrolysis. The data also
strongly suggests that plasma BChE, but not AChE, is the primary enzyme responsible for
the rapid enzymatic hydrolysis of the 3´-phenolic ester of heroin within the blood, which
has led us to exam whether an effective blocker for BChE can be used as a novel therapeutic
strategy for prevention of heroin overdose. Considering that heroin is regarded a prodrug
which acts through its host’s initial metabolites (6-MAM and morphine)264 and that humans
lacking functional BChE appear healthy,337 there is a possibility that human BChE might
be a potential target for prevention of cocaine intoxication, and our animal studies have
produced promising results. In addition, the complete catalytic parameters obtained for
CocH1 against heroin and 6-MAM revealed that concurrent use of heroin and cocaine is
not expected to significantly affect the efficacy of CocH1 in cocaine detoxification.

6.2 Oligomerization and catalytic parameters of human UGT1A10
In the third part of this dissertation, the complete catalytic parameters obtained for

128

recombinant UGT1A10 against therapeutically valuable two drugs, morphine and
entacapone, demonstrated that the catalytic activities of recombinant UGT1A10 proteins
are remarkably different, depending on which type of cell line is used to express the protein.
Added to this, it was observed that recombinant human UGT1A10 protein expressed in
HEK293 cells forms oligomerized complexes that are covalently cross-linked by disulfide
bonds, but that expressed in CHO cells barely forms cross-linked disulfide bonds. Indeed,
these findings are very meaningful in that this is not only the first demonstration of the
oligomerized UGT1A10 complexes, but also the first evidence to show the presence of
complicated disulfide bridges to form higher-order UGT complexes bigger than a dimer.
Given that the covalently cross-linked homo-oligomers are not frequently observed in
hepatic UGT1A1, 1A4, and 1A6 enzymes expressed in HEK293 cells,304 the observed
multiple disulfide bonds formed in the oligomerized complexes of extrahepatic UGT1A10
seem to be unique, which may be the first evidence to show the original differences
between hepatic and extrahepatic UGT enzymes.
HEK293 is one of the most widely used cell lines for characterization of the
enzymatic activity and oligomeric states of multiple human UGT isoforms. The use of the
cell line has enabled us to compare our data with those reported by others. However,
considering that UGT1A10 is an extrahepatic UGT isoform which is highly expressed in
the large and small intestines, we might want to consider including intestinal epithelial cell
lines for the gene expression in order to establish physiological relevance of our in vitro
findings.
6.3 Cancer treatment
The last part of this dissertation is focused on development of a new Par-4 entity
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with a prolonged duration of action for cancer treatment. The results showed that Fc-fusion
substantially prolonged the biological half-life of Par-4 protein. Aglycosylated Fc-fused
Par-4 protein retained not only considerable in vitro and in vivo anti-cancer activity, but
also increased serum persistence in mice, comparable to that of Fc-fused Par-4 protein
prepared from mammalian cells. These data strongly suggest that the E. coli expression
system is capable of producing a potentially therapeutically valuable form of Par-4 protein.
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Chapter VII. Other Unpublished Works

7.1 Development of potential antibody therapeutics for opioid use disorders
7.1.1 The main purpose of this study
The main research goal of this project is to first develop the therapeutic antibody
with high binding affinities for heroin and the psychoactive metabolites of heroin for heroin
and morphine abuse treatment. Then, the discovered antibodies are going to be further
engineered to have more broad specificity toward other opioids of abuse. In this study, I
cloned and purified the protein used, and established the required binding affinity assays
using isotope-labelled morphine ([3H]morphine). Dr. Chunhui Zhang has taken over this
work and further developed the project.

7.1.2 Introduction
Substance use disorder
Continual use of psychoactive drugs can develop addiction. Addiction is defined as
a chronic and relapsing brain disorder which is characterized by uncontrollable drug use,
despite negative consequences. It is regarded a brain disorder since a drug changes the
brain and how it works. These drug-induced changes in the brain can last for a long period
of time and result in dangerous and self-destructive behaviors.
The journey to recovery from substance use disorder
In general, acute withdrawal symptoms occur commonly hours after the last dose
of a drug and diminish within weeks.112-114 Acute withdrawal symptoms are generally
followed by a protracted abstinence syndrome, including insomnia, dysphoria, irritability,
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and fatigue for months. Symptom severity is generally associated with the several factors,
e.g. what kind of narcotic has been used, and how long and much the drug has been abused.
However, patients can abandon their recovery programs and return to drug use at any time
during abstinent periods due to multiple potential factors like the priming effect of a drug,
stress, and drug-related stimuli. This phenomenon is called “relapse”.
Specific goals for substance use disorder treatment
Goals for the treatment of substance use disorder include addressing withdrawal
symptoms and drug craving in a proper way, normalizing physiological function that is
changed in response to continual drug use, and more important, preventing patients against
any exposure to drug again. However, limited success in opioid addiction treatment has
been achieved with current therapeutic options. Historical data show that approximately
85% of patients undergo relapse within 2-years of intensive psychological interventions.338339

Maintenance treatment using opioid agonists (e.g. methadone or buprenorphine) has

produced more promising results, but mean 1-year retention rates are still below 60%.340345

In addition, it has been observed in multiple clinical studies that patients on methadone

maintenance with a history of heroin addiction remain vulnerable to the drug-related
stimuli, such as images of morphine injection, which indicates a continuous vulnerability
of patients on methadone maintenance treatment to relapse by drug-related stimuli through
a day.346-348
Current therapeutic options for illegal/prescription opioid use disorder
-

Opioid antagonist treatment: Naltrexone
Naltrexone is an opioid antagonist approved by the FDA for opioid use disorder

treatment. The hypothesis for the use of an opioid antagonist in the treatment is a means of
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blocking a conditioned response to drug.349 Specifically, if the addicts cannot be successful
in relieving the withdraw symptom- or craving-related negative state through opiate use
because of competitive antagonism at the µ-opioid receptor, the behavior of turning to
opioid in these situations would be considerably reduced. However, multiple clinical trials
of Naltrexone for opioid addition treatment using either daily or thrice weekly schedule
revealed that less than approximately 80% of patients returned to drug use within 6
months.350-352
-

Opioid agonist maintenance treatment: Methadone & Buprenorphine
The FDA has approved two opioid agonists for the long-tern treatment of opioid

use disorder: methadone (a full opioid agonist), and buprenorphine (a partial opioid
agonist). Methadone maintenance therapy (also denoted as “agonist-assisted relapse
prevention treatments”) has produced better outcomes compared to any other intervention.
Buprenorphine is more recently approved for narcotic addiction treatment and has proven
to be as effective as methadone.353-354 It has been demonstrated that both methadone and
buprenorphine considerably reduce both the negative and positive reinforcing effects of
short-acting opioids or natural opiates, and subside craving subsided, enable the addicted
patients to focus on non-drug-related activities.353-354 However, mean 1-year retention rate
in the maintenance treatment is still below 60%.340-345 In addition, many clinical studies
have shown that, at any given time, approximately 15% of patients on methadone
maintenance treatment will have the ongoing use of opiate.355-358
The contributions we would like to make to opioid use disorder problem
In the present study, we have developed antibody therapeutic candidates for opioid
use disorder treatment. An antibody therapeutic is expected to have a mechanism and
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therapeutic utility which distinctly different from the traditional small-molecule
approaches to treatment. It has been demonstrated that antibodies with high binding affinity
for a target opioid are capable to sequestrate the drug in the bloodstream and block the
entry of the drug to the brain, markedly impairing any physiological effects of the drug.267,
359-361

It is expected that the therapeutic antibody would have great potential to become

available for complementing the existing pharmacologic treatment or for complementing
the psychosocial tools needed for a transition to a medication-free and abstinent life.

7.1.3 Results and discussion
Based on the computational modeling and design, our most promising IgG1,
denoted as MMBCmAb-H6M (Fig. 7.2) for convenience, with the overall highest binding
affinities for the three heroin-related opioids, i.e. heroin (Ki = 11.8 nM), 6-MAM (Ki = 11.9
nM), and morphine (Ki = 127 nM) as seen in Fig. 7.2 (panels B to D). Notably, compared
to all of the mAbs reported so far (all with an affinity for 6-MAM at 150-300 nM),362-364
MMBCmAb-H6M has the highest binding affinity for 6-MAM (the most toxic metabolite
of heroin).
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Figure 7.1 SDS-PAGE of the purified mAb MMBCmAb-H6M. The different amounts of
the purified antibody were loaded on the gel and visualized by Coomassie blue staining to
determine its purity before a subsequent binding affinity test.
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Figure 7.2 The modeled structure and in vitro activities of mAb MMBCmAb-H6M: (A)
mAb binding with heroin in which the distances are given in Å (the binding structures with
6-MAM and morphine are very similar to this one); (B) mAb-[3H]morphine binding
saturation data (with [3H]morphine concentration being 2 nM); (C) 6-MAM inhibiting the
mAb-[3H]morphine binding; (D) heroin inhibiting the mAb-[3H]morphine binding. For the
competing binding assays, the [3H]morphine concentration was 2 nM, and the mAb
concentration was 60 nM. All of the error bars of the in vitro data are represented in the
standard deviation (SD).
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7.1.4 Materials and methods
Protein preparation
In our proof-of-principle studies, the mAb (MMBCmAb-H6M) genes were
designed to carry both the heavy and light chains, with an Internal Ribosome Entry Site
(IRES) inserted between them, so that both the heavy and light chains can be expressed at
the same time. The genes were synthesized by GeneArt (Invitrogen), and were cloned into
the pCMV-MCS vector (the same vector used to express many other proteins in our lab)
between the BamHI and SalI sites.
The same experimental procedure365-366 used in our accomplished studies to prepare
various Fc-fusion protein variants was used to prepare MMBCmAb-H6M (and variants) in
this investigation. Briefly, site-directed mutagenesis of the mAb cDNA (in the pCMV-MCS
expression plasmid) was performed by using the QuikChange method.367 Each variant was
expressed in Chinese hamster ovary (CHO) cells in free-style CHO expression medium.
Cells were grown first to a density of ~1.0 × 106 cells/ml in a 2 L shake flask and transfected
using TransIT-PRO Transfectio Kit. Cells were incubated at 37°C in a CO2 incubator for 5
days before the culture medium was harvested. The mAb (MMBCmAb-H6M or variant)
protein expressed in the medium was purified by using MabSelect Protein A resin (GE
Healthcare)38, 40 and analyzed by SDS-PAGE.
In vitro binding assays
The binding of the mAb with [3H]morphine was determined by using liquid
scintillation counting. Briefly, 2 nM [3H]morphine was incubated with a varying
concentration of mAb at room temperature for 60 min, with the total volume of the mixture
being 100 µL and the pH being 7.4. Then, it was filtered with EMD Millipore Amicon™
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Ultra-0.5 Centrifugal Filter (30 kD) and EMD Millipore Amicon™ Ultra 0.5 mL Vials. 50
µL of the filtrate was added to 3 mL of 3a70BTM complete counting cocktail (RPI
Research Products) for liquid scintillation counting. The obtained mAb concentrationdependent data were analyzed by using the GraphPad Prism 7 software to determine the
binding constant.
For the binding affinity of the mAb with other ligands, we first determined IC50 for
each ligand inhibiting the mAb-[3H]morphine binding through a competing binding assay.
Briefly, 100 µL of mixture (pH 7.4) containing 2 nM [3H]morphine, 60 nM mAb (or an
mAb concentration close to the Kd of the mAb-[3H]morphine binding), and a varying
concentration of the ligand under testing was incubated at room temperature for 60 min.
Then the mixture was filtered with EMD Millipore Amicon™ Ultra-0.5 Centrifugal Filter
(30 kD) and EMD Millipore Amicon™ Ultra 0.5 mL Vials, and 50 µL of the filtrate was
added to 3 mL of 3a70BTM complete counting cocktail (RPI Research Products) for liquid
scintillation counting. The IC50 (calculated by using the GraphPad Prism 7 software) was
converted to Ki (or Kd) by using the IC50-to-Ki Converter.368
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7.2 Development of mPGES-1 specific inhibitor as an anticancer agent for multiple
therapeutic areas
7.2.1 The main purpose of this study
A growing body of evidence strongly suggest that prostaglandin E2 (PGE2) plays a
critical role in tumor development including proliferation in multiple types of cancer
cells.369-372 In PGE2 biosynthesis, Cyclooxygenases (COX-1/COX-2) converts arachidonic
acid arachidonic acid (AA) to prostaglandin H2 (PGH2),373 and microsomal PGE-synthase1 (mPGES-1) converts PGH2 to PGE2.374 DU145 (human prostate cancer cell line), LLC1 (murine lung cancer cell line), and A549 (human colon cancer cell line) express
substantial amounts of MPGES-1 in a constitutive manner.369 In the present study, we
wanted to examine the possibility that an mPEGS-1 inhibitor has an anti-tumor activity and
can be utilized for cancer treatment in combination with the first-line therapeutics for lung,
colon, and prostate cancer including Cisplatin, Erlotinib, and Paclitaxel (PTX). I tested one
of the mPGES-1 inhibitors (denoted as BAR002) discovered in our lab. It turned out that
this mPGES-1 inhibitor had only mild anti-proliferation activity, but no strong cytotoxicity
to both DU-145 or A549 cells. In addition, BAR002 did not show a promising synergistic
anti-cancer activity when used in combination with the tested first-line drug.

7.2.2 Results and discussion
Previously, our lab discovered a potent mPEGS-1 inhibitor, denoted as BAR002
here for convenience, whose IC50 value is 33 nM against human mPEGS-1 and 157 nM
against mouse mPGES-1.375-376 First, the cytotoxicity of BAR002, Cisplatin, Erlotinib, and
PTX were determined using MTT assay. Experiments were performed in triplicates and the
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mean half maximal inhibitory concentration (IC50) was utilized to compare cytotoxicity.
The determined IC50 values of these drugs for DU-145 cell growth (after 48 h of exposure)
were summarized in Table 7.1 and depicted in Fig. 7.3. The results show that the IC50 value
of BAR002 for the cell viability was ~23.6 µM, which implies that mPGES-1 inhibition
by BAR002 is unlikely to be very toxic to DU-145 cells.

Figure 7.3 Dose-response curves of Cisplatin, Erlotinib, or PTX in DU-145 cells (48 h of
exposure, n = 3, mean ± SD).
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Table 7.1 IC50 values (μM) of BAR002, Cisplatin, Erlotinib, or PTX after 48 h of exposure
(n = 3, mean ± SD)

DU-145

BAR002

Cisplatin

Erlotinib

PTX

23.56 (±2.43)

4.81 (±0.12)

17.73 (±3.45)

<0.01

To evaluate the effect of combining BAR002 with the tested anti-cancer agents,
DU-145 cells were exposed to a different concentration of Cisplatin, Erlotinib, or PTX in
combination with 0.78 µM BAR002, followed by incubation for 48 h. Considering the low
IC50 value of BAR002 for human mPEGS-1 (33 nM)375 and its IC50 value determined for
the growth of DU-145 cells (~23.6 µM), it is highly expected that BAR002 treatment at 1
µM concentration would strongly inhibit mPGES-1 activity of the cells, but not be
significantly toxic to the cells. According to the results obtained (Fig. 7.4), BAR002 had
subtle synergistic anti-cancer activity (about 10~20%) only with PTX, but not with
Erlotinib or Cisplatin.
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Figure 7.4 Combination assays of BAR002 and anticancer agents Cisplatin, Erlotinib, and
PTX. DU-145 cells were exposed to a different concentration of an anticancer agent with
0.78 µM BAR002.
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The cytotoxicity of BAR002, Cisplatin, Erlotinib, and PTX were also determined
for A549 cells (colon cancer cell line). The determined IC50 values of these drugs for the
cell growth (after 48 h of exposure) were summarized in Table 7.2 (and also Fig. 7.5).
According to the results obtained, A549 than DU-145 cells displayed relatively higher
resistance to apoptotic cell death by the compounds tested. Interestingly, it was also
observed that A549 cells were not completely died even at 25 µM concentration of PTX. I
do not know the reason why some of A549 clonal populations still had such strong
resistance to the high dose of PTX, but this lead me to test whether BAR002 treatment
makes A549 cells more vulnerable to apoptotic cells death by PTX or other anti-cancer
reagents. For this, A549 cells were exposed to different concentrations of Cisplatin,
Erlotinib, or PTX in combination with 0.78 µM BAR002, followed by incubation for 48 h.
The results showed that BAR002 neither increased the sensitivity of A549 cells to celldeath induced by PTX nor displayed significant synergistic anti-cancer activity with
Erlotinib or Cisplatin (Fig. 7.6).
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Figure 7.5 Dose-response curves of Cisplatin, Erlotinib, or PTX in A549 cells (48 h of
exposure, n = 3, mean ± SD).

Table 7.2 IC50 values (μM) of BAR002, Cisplatin, Erlotinib, or PTX after 48 h of exposure
(n = 3, mean ± SD)

A549

BAR002

Cisplatin

Erlotinib

PTX

71.97 (±12.31)

286.1 (±0.12)

49.80 (±9.28)

Unknown
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Figure 7.6 Combination assays of BAR002 and anticancer agents Cisplatin, Erlotinib, and
PTX. A549 cells were exposed to different concentrations of an anticancer agent with 0.78
µM BAR002.
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We also determined whether BAR002 is capable of inhibiting the proliferation of
DU-145 cells. DU-145 cells were treated with the BAR002 concentrations where the
viability of DU-145 cells was not significantly affected. Viability was then measured over
5 days after the cells were exposed to BAR002. According to the results obtained (Fig. 7.7),
proliferation in DU-145 cells was significantly compromised 4 days after exposure to
BAR002. The antiproliferative effect of BAR002 was also observed even at the low
BAR002 concentrations and became more obvious over time, which implies that the onset
of the antiproliferative effect of BAR002 was slow. It is expected that the long-term
BAR002 treatment would produce a more promising tumor growth suppression by the
compound. In the future, we may have to further determine how efficiently BAR002
inhibits PEG2 production in DU-145 cells overtime in the given treatment conditions. The
combined results of the long-term effects of BAR002 on proliferation and PEG2 production
in DU-145 cells will let us know whether there is a positive correlation between those
factors.
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Figure 7.7 Viability was measured over 5 days by MTT reduction after DU-145 cells were
exposed to different concentrations of BAR002 (closed squares) and or controls (closed
circles). Controls consisted of DMSO at the same concentration as in the BAR002treatment experiments. Each experiment was performed in triplicates. Results are presented
as the mean ± S.D. of two separate experiments.

147

7.2.3 Materials and methods
Cell viability assay
Cells were seed onto a 96 well plate. (5000 cells/well). 24hr after cell seeding, the
cells were incubated with differing concentrations of a designated compound for 48hr. Dye
reduction was then initiated by the addition of 20 μL of 5 mg/mL MTS to each well. After
2 h, the developed signals were measured at absorbance at 570 in a micro plate reader.
Cell proliferation assay
Cells were seeded onto 96 well plate (5x103 cells/per) and incubated for 12 hr. The
culture media was exchanged with fresh media right before incubation with different
concentrations of an mPGES-1 inhibitor. The cell growth was measured over 3 days by
MTS assay.
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